[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 870
1. Jiang B, Wu GP, Zhao YJ, Wang SC: Transcription expression and clinical significance of TTF-1 mRNA in pleural effusion of patients with lung cancer. Diagn Cytopathol; 2008 Dec;36(12):849-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcription expression and clinical significance of TTF-1 mRNA in pleural effusion of patients with lung cancer.
  • The aim of this study was to evaluate diagnostic utility of thyroid transcription factor 1 (TTF-1) mRNA in pleural effusions (PEs) of patients with lung cancer, especially primary pulmonary adenocarcinoma (PPA).
  • Transcription levels of TTF-1 were detected by reverse transcription polymerase chain reaction (RT-PCR) in PEs of patients with lung cancer (56 cases) and with lung benign diseases (44 cases).
  • The expression rate of TTF-1 mRNA was significantly higher in PEs of patients with lung cancer (73.2%) than with benign lung diseases (0%).
  • As a molecular marker of detecting pleural micrometastasis, TTF-1 mRNA may be helpful to diagnose the cancer cells in PEs of patients with lung cancer, especially with PPA.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / genetics. Lung Neoplasms / diagnosis. Nuclear Proteins / genetics. Pleural Effusion, Malignant / diagnosis. RNA, Messenger / genetics. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18855882.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


2. Yang DM, Kim HC, Lim JW, Jin W, Ryu CW, Kim GY, Cho H: Sonographic findings of groin masses. J Ultrasound Med; 2007 May;26(5):605-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common benign tumor of the inguinal region was a lipoma.
  • Other benign tumors of the groin included leiomyomas, dermoid cysts, epidermoid cysts, and lymphangiomas.
  • The most common primary malignant tumors in the inguinal region were sarcomas such as rhabdomyosarcoma and liposarcoma.
  • Secondary malignant tumors of the inguinal regions were metastatic lymphomas and metastatic carcinomas of the lung, breast, ovary, and gastrointestinal tract.
  • CONCLUSIONS: Although there was substantial overlap of sonographic findings in the various inguinal masses, clinical history and certain sonographic details can assist in making the correct diagnosis.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460003.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Gradowski JF, Mantha GS, Hunt JL, Dacic S: Molecular alterations in atypical adenomatous hyperplasia occurring in benign and cancer-bearing lungs. Diagn Mol Pathol; 2007 Jun;16(2):87-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular alterations in atypical adenomatous hyperplasia occurring in benign and cancer-bearing lungs.
  • Atypical adenomatous hyperplasia (AAH) is considered to be a precursor lesion of the lung adenocarcinoma.
  • Several genetic abnormalities have been reported in AAH associated with adenocarcinoma, but little is known about AAH associated with benign lung lesions.
  • To address this we compared the molecular characteristics of AAH present in benign conditions to those coexisting with carcinoma.
  • Seven cases of AAH from resected non-neoplastic lungs (AAH-B) and 12 cases from lungs resected for primary lung carcinoma (AAH-M) were analyzed for loss of heterozygosity (LOH) using 21 polymorphic microsatellite markers situated in proximity to known tumor suppressor genes on chromosomes 3p, 5q, 7p, 9p, 10q, and 17p.
  • Our results showed a significant overlap in LOH patterns between AAH with or without coexistent lung malignancy.
  • Therefore, AAH may represent a smoking induced low-grade neoplastic lesion that may be a precursor lesion of only a subset of invasive lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Adenomatosis, Pulmonary / genetics. Loss of Heterozygosity. Lung / pathology. Lung Neoplasms / genetics. Precancerous Conditions / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Genetic Markers / genetics. Humans. Male. Microsatellite Repeats. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525677.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers
  •  go-up   go-down


Advertisement
4. Zhao Y, Liu B, Bian J: [Correlation of time-density curve of CT enhancement with angiogenesis in lung cancer]. Zhongguo Fei Ai Za Zhi; 2007 Jun 20;10(3):206-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of time-density curve of CT enhancement with angiogenesis in lung cancer].
  • BACKGROUND: Newborn blood vessel formation correlates closely with active cellular proliferation of tumor.
  • The aim of this study is to explore the relationship of expression of COX-2 and VEGF, MVD with CT enhancement appearance of lung cancer.
  • METHODS: Dynamic CT scans were evaluated in 25 patients with lung cancer and 35 patients with pulmonary benign disease who underwent complete resection and did not receive any chemotherapy or radiotherapy prior to operation.
  • RESULTS: The levels of COX-2 (P < 0.05), VEGF (P < 0.05), MVD (P < 0.05) and CT enhancement value (P < 0.01) in lung cancer group were significantly higher than those in plumonary benign tumor group.
  • The levels of COX-2, VEGF and MVD were closely related to CT enhancement value, histological type, clinical stages and lymph node metastasis, but not to differentiation grade of lung cancer.
  • CONCLUSIONS: COX-2, VEGF and MVD may be important molecular biological predictors in early diagnosis and prognosis estimation of lung cancer.
  • Dynamic CT enhancement scans can reflect the vascularity characteristics of lung cancer, and it may be helpful to determine the involvement, metastasis and prognosis of lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21118647.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


5. Albert A, Tarrado X, Montaner A, Cáceres F, Parareda A, Cruz O, Mora J, Morales L: [The role of surgery for lung nodules in pediatric oncology]. Cir Pediatr; 2006 Oct;19(4):228-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of surgery for lung nodules in pediatric oncology].
  • [Transliterated title] La cirugía de los nódulos pulmonares en oncología pediátrica.
  • AIM: To evaluate the role of lung nodule surgery in pediatric cancer patients.
  • Clinical data, imaging features, surgical attitude, pathology and outcome were analyzed for those patients developing lung nodules on CT scan at any time.
  • RESULTS: Fifty-seven out of 857 (6.6%) cancer patients had lung nodules at one or more times during their disease course, totalling seventy-five episodes.
  • The primary pathological diagnoses include: Osteosarcoma n = 17, Ewing's sarcoma n = 14, Rhabdomyosarcoma n = 5, Germ cell tumor n = 4, other sarcomas n = 4, Wilms' tumor n = 3, Neuroblastoma n = 3, Lymphoma n = 2.
  • Twenty-nine cases had lung nodules at diagnosis; in 20 they were found during therapy; in 29 concomitant with other sites of relapse off therapy; and in 16 patients as an isolated event during follow-up.
  • Among the nine, five showed either normal lung tissue or scarring after tumor necrosis, and four had other benign diagnoses including: reactive inflammatory cells, pleural lymphangioma, mycobacteria infection and inflammatory pseudotumor.
  • In 39 instances biopsy was not done either because the diagnosis could be made through specific tests, or because the nodules disappeared in a follow-up CT scan within 2 weeks, or because of disease progressing in spite of treatment.
  • In 4 patients surgical removal of lung metastases has afforded cure.
  • CONCLUSIONS: Lung nodule surgery plays a fundamental role in the management of patients with pediatric malignancies: it allows accurate staging, avoiding overtreatment in more than 15% of the cases, and gives a higher chance of cure in some patients.
  • [MeSH-major] Lung Neoplasms / surgery. Solitary Pulmonary Nodule / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352112.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


6. Klöppel G: Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab; 2007 Mar;21(1):15-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour biology and histopathology of neuroendocrine tumours.
  • In the lung they are called carcinoid and small/large-cell neuroendocrine carcinomas.
  • Their clinical behaviour--ranging from benign and low-grade to high-grade malignancy--can be predicted on the basis of clinicopathological criteria.
  • [MeSH-major] Neuroendocrine Tumors / pathology
  • [MeSH-minor] Biomarkers / analysis. Biomarkers, Tumor / analysis. Carcinoma / classification. Carcinoma / diagnosis. Carcinoma / genetics. Carcinoma / pathology. Gastrointestinal Neoplasms / classification. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / genetics. Gastrointestinal Neoplasms / pathology. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Neurosecretory Systems / cytology. Prognosis. Respiratory Tract Neoplasms / classification. Respiratory Tract Neoplasms / diagnosis. Respiratory Tract Neoplasms / genetics. Respiratory Tract Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17382263.001).
  • [ISSN] 1521-690X
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor
  • [Number-of-references] 48
  •  go-up   go-down


7. Gérard R, Keller A, Taylor S, Hoffmeyer P, Peter R: [Ischemic eosinophilic granuloma and pulmonary histiocytosis with a regressive course]. Rev Chir Orthop Reparatrice Appar Mot; 2007 Sep;93(5):501-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Langerhans' histiocytosis or histiocytosis X is a rare intrinsically benign disease producing a destructive tumor with a variable clinical presentation and an often unpredictable clinical course.
  • The lung disease led to the initial diagnosis and optimal surgical, pathological and radiological management.
  • [MeSH-minor] Adolescent. Bone Transplantation. Humans. Ischium / radiography. Ischium / surgery. Magnetic Resonance Imaging. Male. Osteolysis / diagnosis. Osteolysis / etiology. Osteotomy. Pelvic Bones / radiography. Radiography, Abdominal. Radiography, Thoracic. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Histiocytosis.
  • Genetic Alliance. consumer health - Langerhans cell histiocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17878842.001).
  • [ISSN] 0035-1040
  • [Journal-full-title] Revue de chirurgie orthopédique et réparatrice de l'appareil moteur
  • [ISO-abbreviation] Rev Chir Orthop Reparatrice Appar Mot
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


8. Hu R, Li H: Giant cystic hemolymphangioma of the postmediastinum. Thorac Cancer; 2010 Nov;1(4):175-177
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography (CT) of the chest revealed a mediastinal tumor identified a giant non-invasive monomorphic cystic mass, in contact with the tracheal wall, arcus aortae and subclavian artery.
  • Partial excision of the mass was achieved through left thorascopic exploration, Frozen section margin examination suggests hemolymphangioma, which is a benign tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Tianjin Lung Cancer Institute and Blackwell Publishing Asia Pty. Ltd.
  • (PMID = 27755814.001).
  • [ISSN] 1759-7714
  • [Journal-full-title] Thoracic cancer
  • [ISO-abbreviation] Thorac Cancer
  • [Language] eng
  • [Publication-type] Case Reports
  • [Publication-country] Singapore
  • [Keywords] NOTNLM ; Hemolymphangioma / mediastinum / treatment
  •  go-up   go-down


9. Zhang P, Han Y, Huang L, Li Q, Ma D: [Expression and Clinical Significance of TTF-1 and p63 in NSCLC.]. Zhongguo Fei Ai Za Zhi; 2009 Sep 20;12(9):995-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To detect the expressions of thyroid transcription factor-1 (TTF-1) and p63 in non-small cell lung cancer (NSCLC) and to evaluate their clinical significance.
  • METHODS: The expression of TTF-1 and p63 from 404 NSCLC and 28 benign pulmonary disease (BPD) tissue specimens were detected by immunohistochemical EnVision two-step method, together with their clinicopathologic data.
  • Its sensitivity and specificity to squamous cell carcinoma (SCC) was 95.5% and 98.8%, respectively, which was positively correlated with differentiation of SCC (P=0.008), but negatively with tumor stage (P=0.002).
  • They may be a useful marker panel for the identification and differential of lung cancer.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20719198.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


10. Chen JF, Zhang LJ, Zhao AL, Wang Y, Wu N, Xiong HC, Liang Z, Li JY, Huang XF, Yang Y: [Abnormal expression of Thy-1 as a novel tumor marker in lung cancer and its prognostic significance]. Zhonghua Yi Xue Za Zhi; 2005 Jul 20;85(27):1921-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Abnormal expression of Thy-1 as a novel tumor marker in lung cancer and its prognostic significance].
  • OBJECTIVE: The purpose of this study was to investigate the expression of Thy-1 immunohistochemically in different lung tumors and its prognostic significance in non-small cell lung cancer (NSCLC) cases.
  • METHODS: In this study, we used anti-Thy-1/CD90 antibody to detect the expression pattern of Thy-1 in different lung tumor sections, which were embedded in paraffin blocks.
  • The expressions of Thy-1 in 175 lung tissue cases, including different pathological types, were analyzed as tissue array form.
  • RESULTS: We first found that anti-Thy-1 antibody can strongly stain a nuclear molecule in different type of lung cancer cells.
  • Among lung cancer cases, 89 (56.7%) cases showed strong nuclear staining for Thy-1 specially.
  • CONCLUSION: There is a significant overexpressed Thy-1 located in lung cancer cell nucleus as compared to the normal tissue or benign tumor cells of lung, and it is one of the factors effected on the prognosis of NSCLC patients.
  • This finding suggests that Thy-1 maybe a novel latent malignant marker in the lung cancer pathology.
  • [MeSH-major] Antigens, Thy-1 / metabolism. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Lung / metabolism. Lung / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16255990.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Thy-1; 0 / Biomarkers, Tumor; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


11. Carney JA: Carney triad: a syndrome featuring paraganglionic, adrenocortical, and possibly other endocrine tumors. J Clin Endocrinol Metab; 2009 Oct;94(10):3656-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carney triad: a syndrome featuring paraganglionic, adrenocortical, and possibly other endocrine tumors.
  • BACKGROUND: Two young women, each with paraganglioma and gastric stromal tumor, were encountered in the middle 1970s.
  • OBJECTIVE: To test the hypothesis that the combination of tumors might represent a rare syndrome, similar cases were searched for.
  • Five additional patients with gastric stromal tumor, paraganglioma, and pulmonary chondroma were found, and all were young women.
  • None had a family history of the tumors.
  • The combination of the three tumors was later referred to as the Carney triad.
  • The gastric lesion was usually the presenting tumor (75%), followed by the lung lesion (15%) and the paraganglionic tumor (10%).
  • All the tumors were multifocal.
  • The gastric and paraganglionic tumors metastasized in one third and one tenth of the patients, respectively.
  • The pulmonary tumors were asymptomatic and benign.
  • FOLLOW-UP: At follow-up, 80% of the patients were alive, two thirds with pulmonary chondroma, 25% with metastatic or residual gastric stromal tumor, and 5% with primary or metastatic paraganglioma.
  • Twenty percent of the patients were dead, usually from metastatic gastric stromal tumor, less frequently from metastatic paraganglioma.
  • CONCLUSION: The Carney triad is a chronic, persistent, indolent but sometimes fatal disorder of unknown etiology.
  • [MeSH-major] Adenoma. Adrenal Cortex Neoplasms. Chondroma. Esophageal Neoplasms. Leiomyoma. Lung Neoplasms. Multiple Endocrine Neoplasia. Neoplastic Syndromes, Hereditary / pathology. Paraganglioma
  • [MeSH-minor] Adolescent. Carotid Body Tumor / pathology. Chronic Disease. Female. Follow-Up Studies. Gastrointestinal Stromal Tumors / pathology. Humans. Male. Pheochromocytoma / secondary

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for carney triad .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19723753.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


12. Sattar HA, Yang DL, Husain AN, Redleaf MI, Dayal VS: Multiple paragangliomata of the lungs and temporal bone. Ear Nose Throat J; 2008 Nov;87(11):E4-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of a 71-year-old woman with multiple benign lung paragangliomata and a benign glomus jugulare paraganglioma in one temporal bone that mimicked a malignancy.
  • The patient's lung lesions did not regress with chemotherapy.
  • Subsequent histologic markers suggested several very slowly dividing tumors.
  • A finding of multiple lung paragangliomata should raise the suspicion of a multicentric rather than malignant tumor.
  • [MeSH-major] Lung Neoplasms / secondary. Paraganglioma, Extra-Adrenal / pathology. Skull Neoplasms / secondary. Temporal Bone / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19006054.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Donthineni R, Boriani L, Ofluoglu O, Bandiera S: Metastatic behaviour of giant cell tumour of the spine. Int Orthop; 2009 Apr;33(2):497-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic behaviour of giant cell tumour of the spine.
  • Lung metastases from giant cell tumours (GCT) of the spine have not been specifically addressed in the literature.
  • Between 1970 and 2006, we identified seven cases (three females and four males) of lung metastases from a total of 51 cases of GCT of the spine (13.7%).
  • The treatments for the lung nodules consisted of metastectomy in two and chemotherapy in six patients.
  • Our series shows a higher metastatic rate from spine GCT as compared to those from the extremities, but the overall behaviour and treatment outcomes of the lung metastases are similar.
  • When there is a recurrence of GCT, with or without metastases, the local and possibly the metastases should be biopsied to confirm the original diagnosis.
  • Progression of benign GCT into an aggressive sarcoma has been documented, and the method of management should be altered.
  • [MeSH-major] Bone Neoplasms / pathology. Giant Cell Tumor of Bone / secondary. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adolescent. Adult. Biopsy, Needle. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Assessment. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 2002 Aug;(401):202-8 [12151897.001]
  • [Cites] Int Orthop. 2006 Dec;30(6):499-504 [16909252.001]
  • [Cites] J Bone Joint Surg Am. 1975 Mar;57(2):167-73 [1112843.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1641-9 [7417958.001]
  • [Cites] J Bone Joint Surg Am. 1984 Feb;66(2):269-74 [6693454.001]
  • [Cites] Clin Orthop Relat Res. 1988 Dec;(237):275-85 [3056645.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):204-5 [2249533.001]
  • [Cites] AJR Am J Roentgenol. 1992 Feb;158(2):331-4 [1729794.001]
  • [Cites] J Bone Joint Surg Br. 1993 Jan;75(1):148-54 [8421014.001]
  • [Cites] Clin Orthop Relat Res. 1994 May;(302):219-30 [8168305.001]
  • [Cites] Int Orthop. 1996;20(3):172-6 [8832321.001]
  • [Cites] Clin Orthop Relat Res. 1997 Feb;(335):253-61 [9020226.001]
  • [Cites] Clin Orthop Relat Res. 1997 May;(338):205-14 [9170381.001]
  • [Cites] J Bone Joint Surg Br. 1998 Jan;80(1):43-7 [9460951.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Oct;116(4):649-51 [9766596.001]
  • [Cites] Cancer. 1964 Apr;17:461-72 [14136529.001]
  • [Cites] Clin Orthop Relat Res. 2005 Sep;438:116-22 [16131879.001]
  • [Cites] J Bone Joint Surg Am. 1970 Jun;52(4):619-64 [5479455.001]
  • (PMID = 18461324.001).
  • [ISSN] 1432-5195
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2899057
  •  go-up   go-down


14. Folpe AL, Mentzel T, Lehr HA, Fisher C, Balzer BL, Weiss SW: Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol; 2005 Dec;29(12):1558-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This family of tumors includes angiomyolipoma (AML), clear cell sugar tumor of the lung (CCST), lymphangioleiomyomatosis (LAM), and very rare tumors in other locations.
  • The tumors ranged from 1.6 to 29 cm in size (median, 7.8 cm).
  • Tumors were epithelioid (N = 9), spindled (N = 7), or mixed (N = 10).
  • Recurrence and/or metastasis was strongly associated tumor size > median size (8 cm), mitotic activity greater than 1/50 HPF, and necrosis.
  • We conclude that PEComas of soft tissue and gynecologic origin may be classified as "benign," "of uncertain malignant potential," or "malignant."
  • Small PEComas without any worrisome histologic features are most likely benign.
  • [MeSH-major] Biomarkers, Tumor / analysis. Epithelioid Cells / pathology. Genital Neoplasms, Female / pathology. Neoplasms, Connective and Soft Tissue / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Mitosis. Neoplasm Metastasis. Neoplasm Recurrence, Local. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome. Tumor Burden

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327428.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 56
  •  go-up   go-down


15. Hara R, Matsuguma H, Suzuki H, Ishikawa Y, Nakahara R, Yamaguchi T, Hirabayashi K: Desmoid tumor presenting as a superior sulcus tumor: a unique bone change in the vertebral body. Ann Thorac Surg; 2007 Nov;84(5):1752-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoid tumor presenting as a superior sulcus tumor: a unique bone change in the vertebral body.
  • Desmoid tumor, also referred to as aggressive fibromatosis, is a relatively rare, locally infiltrative, histologically benign tumor.
  • This report details a case of desmoid tumor presented as a superior sulcus tumor, which showed a unique manifestation in the vertebral bodies on computed tomography.
  • [MeSH-major] Fibromatosis, Aggressive / pathology. Lung Neoplasms / pathology. Spine / pathology

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954107.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


16. Matsuda E, Okabe K, Kobayashi S, Hirazawa K, Yamamoto H, Tao H, Murakami T, Sugi K: [Pulmonary hamartoma associated with lung cancer]. Kyobu Geka; 2010 Sep;63(10):875-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary hamartoma associated with lung cancer].
  • Pulmonary hamartoma is most common benign tumor of the lung and is not recognised as having a character of malignant transformation.
  • So, longtime radiological observation is not uncommon for patients with diagnosis of pulmonary hamartoma from computed tomography (CT) finding.
  • Although pulmonary hamartoma does not transform to malignancy, high frequency of coexistence hamartoma and lung cancer has been reported.
  • We experienced 14 cases of resected pulmonary hamartoma, and 3 of them had lung cancer, showing that 21.4% of pulmonary hamartoma coexisted with lung cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Hamartoma / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845697.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Wang Q, Huang LL, Yue MG, Qin SL, Wang Y, Nie YX, Zhang CQ, Liang TJ, Zhao YM: [18F-FDG imaging by coincidence circuit SPECT with low-dose CT in preoperative assessment of pulmonary lesions]. Zhonghua Zhong Liu Za Zhi; 2006 Dec;28(12):924-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the clinical diagnostic value of 18F-FDG imaging by coincidence circuit SPECT with low-dose CT in differential diagnosis of pulmonary lesions and mediastinal lymph node involvement, which can not be definitely diagnosed based on regular CT image in patients with non-small-cell lung cancer (NSCLC).
  • METHODS: By using GE-Millennium VG with Hawkeye, 18F-FDG imaging was carried out in 48 patients with suspected lung cancer.
  • RESULTS: Final pathologic diagnoses of these patients were 36 malignancies consisting of 20 adenocarcinomas, 12 squamous cell carcinomas, 3 small cell carcinomas and I large cell carcinoma; 12 benign tumors including 6 pneumonias, 2 tuberculosis, 2 hamatomas, 1 cyst and 1 neurofibroma.
  • Correct diagnosis were made in 34 malignancies and 6 false positive lesions were excluded based on morphology and 18F-FDG uptake status of the lesion.
  • The sensitivity, specificity and accuracy of the 18F-FDG imaging for differentiating malignant tumor from benign was 94.4%, 50.0% and 83.3%, respectively.
  • CONCLUSION: 18F-FDG imaging by coincidence circuit SPECT with low-dose CT is quite helpful in differential diagnosis for patient with undetermined lesion on regular CT image, but it is limited for staging of lung cancer in the patients with non-small cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Fluorodeoxyglucose F18. Lung Neoplasms / diagnosis. Pneumonia / diagnosis. Tomography, Emission-Computed, Single-Photon / methods
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Lung / pathology. Lung / radiography. Lung / radionuclide imaging. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Radiation Dosage. Radiopharmaceuticals. Retrospective Studies. Sensitivity and Specificity. Tomography, X-Ray Computed. Tuberculosis, Pulmonary / diagnosis. Tuberculosis, Pulmonary / radiography. Tuberculosis, Pulmonary / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17533745.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


18. Prisadov GC, Landes T, Kruger G: Thoracoscopic resection of solitary pulmonary nodules in patients with previous malignant tumors. Folia Med (Plovdiv); 2010 Oct-Dec;52(4):23-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thoracoscopic resection of solitary pulmonary nodules in patients with previous malignant tumors.
  • Round opacities in the lungs found in the course of a neoplastic disorder or during the initial tumor staging are most often regarded as metastases without histological studies to prove their nature.
  • These presumed metastases are, however, very often diagnosed later as benign lesions or primary malignant pulmonary tumors.
  • METHOD: The study included 22 patients with solitary pulmonary nodules and history of previous malignant tumors who underwent video-assisted thoracoscopic surgery at the Clinic of Vascular and Thoracic Surgery, University Hospital Aschersleben, Germany between 01.01.2006 and 31.12.2009.
  • RESULTS: A diagnosis of pulmonary metastasis was confirmed in only 8 of the patients (36.4%).
  • In another 8 of them (36.4%) the solitary pulmonary nodule proved to be a primary lung cancer, i.e. a second malignant tumor.
  • The bronchial carcinoma was synchronous with the primary tumor in four of these patients, and metachronous in the rest.
  • In the other 6 patients (27.2%) the lesions proved to be benign.
  • In benign lesions video-assisted thoracoscopic resection is the definitive medical procedure too.
  • [MeSH-major] Lung Neoplasms / secondary. Neoplasms / pathology. Solitary Pulmonary Nodule / secondary. Thoracic Surgery, Video-Assisted

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21462888.001).
  • [ISSN] 0204-8043
  • [Journal-full-title] Folia medica
  • [ISO-abbreviation] Folia Med (Plovdiv)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


19. Paláu MA, Merino MJ, Quezado M: Corticotropin-producing pulmonary gangliocytic paraganglioma associated with Cushing's syndrome. Hum Pathol; 2006 May;37(5):623-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gangliocytic paraganglioma (GP) is an unusual tumor in the wide spectrum of neuroendocrine neoplasms.
  • The biologic behavior and histogenesis of this tumor is uncertain because, despite its benign histologic features, there have been reports of metastases to regional lymph nodes and distant metastases.
  • Although most of these tumors have been reported in the duodenum, examples of GP arising in extra-ampullary sites have been well documented.
  • Herein, we report the case of a lung GP corticotropin producing and presenting as Cushing's syndrome.
  • After removal of the tumor, there was a significant drop in cortisol and corticotropin levels.
  • [MeSH-major] Adrenocorticotropic Hormone / metabolism. Cushing Syndrome / pathology. Lung Neoplasms / pathology. Paraganglioma / pathology


20. Prisadov G, Uchikov A, Atliev K, Paskalev G, Dimitrov I, Bonev P, Batashki A: [VATS in patients with solitary periferal pulmonary tumors]. Khirurgiia (Sofiia); 2010;(4-5):5-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [VATS in patients with solitary periferal pulmonary tumors].
  • The patients with periferal solitary pulmonary nodule often present a serious diagnostic and therapeuthic challenge.The aim of our study is to present our experience in VATS for diagnosis and treatment of patients with solitary periferal pulmonary tumors.
  • MATERIAL AND METHODS: For the period of 1997-2009, 146 patients with periferal pulmonary tumors underwent VATS for resection of the tumor.
  • RESULTS: 112 (74.2%) of the patients underwent radical VATS resection of the tumor after intraoperative frozen sections for diagnosis.
  • 54.55% of the resected tumors were malignant and 45.45% of them were benign.
  • In 18 patients the intraoperative frozen sections confirmed primary lung cancer, and the procedure was converted to thoracotomy and radical resection.
  • In 13 patients the results from the intraoperative frozen sections were not definite and we were not able to differ wether the tumor was a pulmonary metastase or a primary lung cancer, and after the final histological examination the patients were submitted to radical resection in interval.
  • In 33 of the cases we resected pulmonary metastases from an extrapulmonary primary tumor.
  • CONCLUSIONS: Despite the advances in diagnostic technics, only the VATS resection of the pulmonary tumor and the histological examination assures definitive diagnosis, it allows the definitive treatment for the benign lesions and indicates the correct treatment for malignant lesions.
  • [MeSH-major] Lung / surgery. Lung Neoplasms / diagnosis. Lung Neoplasms / surgery. Solitary Pulmonary Nodule / diagnosis. Solitary Pulmonary Nodule / surgery. Thoracic Surgery, Video-Assisted

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21972676.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


21. Plathow C, Schoebinger M, Herth F, Tuengerthal S, Meinzer HP, Kauczor HU: Estimation of pulmonary motion in healthy subjects and patients with intrathoracic tumors using 3D-dynamic MRI: initial results. Korean J Radiol; 2009 Nov-Dec;10(6):559-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of pulmonary motion in healthy subjects and patients with intrathoracic tumors using 3D-dynamic MRI: initial results.
  • OBJECTIVE: To estimate a new technique for quantifying regional lung motion using 3D-MRI in healthy volunteers and to apply the technique in patients with intra- or extrapulmonary tumors.
  • MATERIALS AND METHODS: Intraparenchymal lung motion during a whole breathing cycle was quantified in 30 healthy volunteers using 3D-dynamic MRI (FLASH [fast low angle shot] 3D, TRICKS [time-resolved interpolated contrast kinetics]).
  • An analysis of lung motion was performed and correlated with an established 2D-MRI technique for verification.
  • As a proof of concept, the technique was applied in five patients with non-small cell lung cancer (NSCLC) and 5 patients with malignant pleural mesothelioma (MPM).
  • RESULTS: The correlation between intraparenchymal lung motion of the basal lung parts and the 2D-MRI technique was significant (r = 0.89, p < 0.05).
  • Also, the vector color maps quantitatively illustrated regional lung motion in all healthy volunteers.
  • The patients with NSCLC showed a local lack of lung motion in the area of the tumor.
  • In the patients with MPM, there was global diminished motion of the tumor bearing hemithorax, which improved significantly after chemotherapy (CHT) (assessed by the 2D- and 3D-techniques) (p < 0.01).
  • CONCLUSION: A 3D-dynamic MRI is able to quantify intraparenchymal lung motion.
  • Local and global parenchymal pathologies can be precisely located and might be a new tool used to quantify even slight changes in lung motion (e.g. in therapy monitoring, follow-up studies or even benign lung diseases).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / physiopathology. Imaging, Three-Dimensional. Lung Neoplasms / physiopathology. Magnetic Resonance Imaging / methods. Mesothelioma / physiopathology. Movement / physiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 2001 Mar;13(3):467-74 [11241824.001]
  • [Cites] Magn Reson Med. 2007 Sep;58(3):631-5 [17685425.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):335-41 [12738306.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Strahlenther Onkol. 2003 Aug;179(8):542-7 [14509953.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):968-78 [14575827.001]
  • [Cites] Acad Radiol. 2003 Oct;10(10):1147-52 [14587632.001]
  • [Cites] Invest Radiol. 2004 Apr;39(4):202-9 [15021323.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):952-9 [15234028.001]
  • [Cites] Eur Radiol. 2004 Aug;14(8):1392-9 [15127220.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):335-41 [15337573.001]
  • [Cites] Am Rev Respir Dis. 1987 Oct;136(4):867-71 [3662240.001]
  • [Cites] Radiology. 1989 Jun;171(3):841-5 [2717762.001]
  • [Cites] Clin Chest Med. 1990 Sep;11(3):405-16 [2205439.001]
  • [Cites] J Magn Reson Imaging. 1999 Oct;10(4):510-20 [10508317.001]
  • [Cites] Radiother Oncol. 2004 Dec;73(3):349-54 [15588881.001]
  • [Cites] Invest Radiol. 2005 Jan;40(1):40-8 [15597019.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):594-607 [15667982.001]
  • [Cites] Invest Radiol. 2005 Mar;40(3):173-9 [15714092.001]
  • [Cites] Med Image Anal. 2005 Dec;9(6):594-604 [15896995.001]
  • [Cites] Invest Radiol. 2006 May;41(5):443-8 [16625107.001]
  • [Cites] Radiology. 2006 Aug;240(2):537-45 [16801367.001]
  • [Cites] Eur Radiol. 2006 Sep;16(9):1942-50 [16628438.001]
  • [Cites] Methods Inf Med. 2007;46(3):275-81 [17492112.001]
  • [Cites] Inf Process Med Imaging. 2007;20:1-12 [17633684.001]
  • [Cites] Curr Opin Oncol. 2003 Mar;15(2):131-8 [12601277.001]
  • (PMID = 19885311.001).
  • [ISSN] 2005-8330
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2770821
  • [Keywords] NOTNLM ; Biomechanics / Dynamic MRI / Intraparenchymal lung motion / Pleural mesothelioma / Tumor
  •  go-up   go-down


22. Yoon Y, Curry K: Concurrence of granular cell tumor and Mycobacterium tuberculosis. South Med J; 2005 Oct;98(10):1034-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrence of granular cell tumor and Mycobacterium tuberculosis.
  • Granular cell tumors (GCT) are rare, usually benign neoplasms of Schwann cell origin.
  • Since discovery in 1926, fewer than 80 cases of GCT involving the lung have been reported.
  • Chest radiography revealed a 3 x 4 cm left upper lobe lung mass with an unremarkable right lung field.
  • This report reviews the literature regarding GCT and presents this unusual case of granular cell tumor co-occurring with active tuberculosis.
  • [MeSH-major] Granular Cell Tumor / complications. Tuberculosis / complications
  • [MeSH-minor] Antitubercular Agents / therapeutic use. Bronchoscopy. Ethambutol / therapeutic use. Humans. Isoniazid / therapeutic use. Lung / drug effects. Lung / pathology. Male. Middle Aged. Mycobacterium tuberculosis / isolation & purification. Pyrazinamide / therapeutic use. Rifampin / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Tuberculosis.
  • Hazardous Substances Data Bank. RIFAMPIN .
  • Hazardous Substances Data Bank. ISONIAZID .
  • Hazardous Substances Data Bank. ETHAMBUTOL .
  • Hazardous Substances Data Bank. PYRAZINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16295820.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antitubercular Agents; 2KNI5N06TI / Pyrazinamide; 8G167061QZ / Ethambutol; V83O1VOZ8L / Isoniazid; VJT6J7R4TR / Rifampin
  •  go-up   go-down


23. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lung and intraabdominal organs are most frequently affected.
  • CASE REPORT: In March 1996, a 37 year-old male underwent surgical resection for a left occipital intraventricular benign meningioma (WHO I).
  • Advice from a second pathologist was seeked, who suggested the diagnosis of intraosseous meningioma.
  • Workup studies failed to reveal any primary tumor.
  • In May 2004 the patient was admitted to our department and a new transpedicular biopsy confirmed the diagnosis.
  • Definite pathology: benign meningioma (WHO I).
  • DISCUSSION: Distant metastases from intracranial meningiomas are rare entities, arising from benign lesions in, at least, 60% of cases.
  • Enam et al proposed a specific pathological score to differentiate benign, atypic and malignant meningiomas.
  • Such score correlates with the chance of metastatizing: more than 40% in malignant meningiomas compared to 3.8% of brain tumors overall.
  • Hematogenous (especially venous; Batson's perivertebral plexus), linfatic and cerebrospinal fluid are the main routes involved in the spreading of the tumor.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Review Literature as Topic

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


24. Kawano K, Ono K, Yada N, Takahashi Y, Kashima K, Yokoyama S, Yanagisawa S: Malignant calcifying epithelial odontogenic tumor of the mandible: report of a case with pulmonary metastasis showing remarkable response to platinum derivatives. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jul;104(1):76-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant calcifying epithelial odontogenic tumor of the mandible: report of a case with pulmonary metastasis showing remarkable response to platinum derivatives.
  • We describe a case of CEOT of the mandible, which underwent malignant transformation and developed metastatic tumors of the lung after repeated local recurrence.
  • The primary tumor revealed typical histological features of benign CEOT showing sheets of polyhedral epithelial cells associated with abundant eosinophilic amyloid-like materials.
  • On the other hand, the locally recurrent tumors had malignant features, such as increased nuclear pleomorphism with frequent mitotic figures and vascular invasion of tumor cells, as well as increased proliferative activity assessed by immunostaining for Ki-67.
  • To date, a total of 6 courses of CDDP and 6 courses of nedaplatin (CDGP) have been done, and the remaining pulmonary tumors have been dormant.
  • This suggests that platinum derivatives could be a chemotherapeutic agent of choice against this rare tumor.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Lung Neoplasms / drug therapy. Mandibular Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Odontogenic Cyst, Calcifying / drug therapy

  • Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577547.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


25. Situ DR, Long H, Ma GW, Lin ZC, Yun JP, Rong TH: [Diagnosis and therapeutics of 24 cases of pulmonary sclerosing hemangioma]. Ai Zheng; 2008 Aug;27(8):861-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and therapeutics of 24 cases of pulmonary sclerosing hemangioma].
  • BACKGROUND & OBJECTIVE: Pulmonary sclerosing hemangioma (PSH) is an uncommon benign lung tumor.
  • The study was to investigate the clinical features, diagnosis, treatment, and prognosis of PSH in order to promote the recognition of this disease.
  • The clinical features, diagnosis, treatment, and prognosis were summarized.
  • Eight patients underwent lobectomy, 13 underwent wedge resection, two underwent tumor resection and one underwent segmentectomy.
  • Thus, accurate diagnosis of PSH before operation is difficult.
  • [MeSH-major] Pneumonectomy / methods. Pulmonary Sclerosing Hemangioma / diagnosis. Pulmonary Sclerosing Hemangioma / surgery

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18710622.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


26. Yang TM, Leu SW, Li JM, Hung MS, Lin CH, Lin YC, Huang TJ, Tsai YH, Yang CT: WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions. J Cancer Res Clin Oncol; 2009 Jul;135(7):919-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions.
  • PURPOSE: Malignant pleural effusion is an important staging criterion in non-small cell lung cancer (NSCLC).
  • METHODS: We performed WIF-1 promoter region MSP in 36 definite malignant pleural effusions from consecutive NSCLC patients and 35 pleural effusion specimens of benign origin.
  • In addition, the results of WIF-1 promoter region MSP were negative in all 35 patients with pleural effusion of benign origin.
  • CONCLUSIONS: WIF-1 promoter region MSP might be used as an adjuvant tool to complement cytologic examination for the diagnosis of NSCLC-related malignant pleural effusion.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Biomarkers, Tumor / genetics. Carcinoma, Non-Small-Cell Lung / diagnosis. DNA Methylation. Lung Neoplasms / diagnosis. Pleural Effusion, Malignant / diagnosis. Promoter Regions, Genetic. Repressor Proteins / genetics
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Sensitivity and Specificity. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncologist. 2005 Aug;10(7):501-7 [16079317.001]
  • [Cites] Cancer Lett. 2005 May 10;222(1):1-10 [15837535.001]
  • [Cites] Thorax. 2008 Jan;63(1):35-41 [17573438.001]
  • [Cites] Thorax. 2003 May;58 Suppl 2:ii8-17 [12728146.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3118-23 [14973184.001]
  • [Cites] J Mol Diagn. 2005 Oct;7(4):517-24 [16237222.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):47-50 [9815536.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Apr;129(4):199-221 [12707770.001]
  • [Cites] Eur Respir J. 2003 Sep;22(3):422-6 [14516130.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 10;341(2):635-40 [16427602.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1761-6 [16708382.001]
  • [Cites] Oncogene. 2002 Sep 26;21(43):6598-605 [12242657.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34 [12775774.001]
  • [Cites] Int J Cancer. 2007 May 15;120(10):2191-5 [17285579.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4717-20 [15256437.001]
  • [Cites] Ann Thorac Surg. 2005 Oct;80(4):1241-7 [16181847.001]
  • [Cites] Ann Thorac Surg. 2005 Apr;79(4):1180-8; discussion 1180-8 [15797047.001]
  • [Cites] J Pathol. 2003 Oct;201(2):204-12 [14517837.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):279-88 [12086864.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6087-92 [17947472.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):413-5 [15913841.001]
  • [Cites] Carcinogenesis. 2008 May;29(5):895-904 [18308762.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):1-9 [16893591.001]
  • (PMID = 19085002.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / Repressor Proteins; 0 / WIF1 protein, human
  •  go-up   go-down


27. Philippar U, Roussos ET, Oser M, Yamaguchi H, Kim HD, Giampieri S, Wang Y, Goswami S, Wyckoff JB, Lauffenburger DA, Sahai E, Condeelis JS, Gertler FB: A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev Cell; 2008 Dec;15(6):813-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The spread of cancer during metastatic disease requires that tumor cells subvert normal regulatory networks governing cell motility to invade surrounding tissues and migrate toward blood and lymphatic vessels.
  • Here we show that Mena and Mena(INV) promote carcinoma cell motility and invasiveness in vivo and in vitro, and increase lung metastasis.
  • Mena and Mena(INV) potentiate epidermal growth factor (EGF)-induced membrane protrusion and increase the matrix degradation activity of tumor cells.
  • Upregulation of Mena(INV) could therefore enable tumor cells to invade in response to otherwise benign EGF stimulus levels.

  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2004 Aug;5(8):647-57 [15366708.001]
  • [Cites] Clin Exp Metastasis. 2009;26(2):153-9 [18985426.001]
  • [Cites] J Natl Cancer Inst. 1982 Mar;68(3):507-17 [6950180.001]
  • [Cites] J Biol Chem. 1994 May 20;269(20):14509-17 [8182057.001]
  • [Cites] Clin Exp Metastasis. 1996 Jan;14(1):61-72 [8521618.001]
  • [Cites] Cell. 1996 Oct 18;87(2):227-39 [8861907.001]
  • [Cites] J Cell Sci. 1998 Jan;111 ( Pt 2):199-211 [9405304.001]
  • [Cites] FEBS Lett. 1999 May 14;451(1):68-74 [10356985.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):23549-57 [10438535.001]
  • [Cites] Exp Cell Res. 1999 Aug 25;251(1):234-43 [10438589.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8585-94 [15574765.001]
  • [Cites] J Cell Biol. 2005 Jan 31;168(3):441-52 [15684033.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2445-59 [15753456.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5278-83 [15958574.001]
  • [Cites] BMC Biotechnol. 2005;5:14 [15910685.001]
  • [Cites] J Biol Chem. 2005 Aug 5;280(31):28653-62 [15939738.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1470-8 [16533770.001]
  • [Cites] Eur J Cell Biol. 2006 Apr;85(3-4):213-8 [16546563.001]
  • [Cites] Bioessays. 2006 Apr;28(4):378-86 [16547952.001]
  • [Cites] J Cell Biol. 2006 May 8;173(3):395-404 [16651380.001]
  • [Cites] Curr Biol. 2006 Nov 21;16(22):2193-205 [17113383.001]
  • [Cites] Trends Cell Biol. 2007 Mar;17(3):107-17 [17275303.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2649-56 [17363585.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2657-65 [17363586.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3505-11 [17440055.001]
  • [Cites] Development. 2007 Jun;134(11):2027-39 [17507404.001]
  • [Cites] Mol Biol Cell. 2007 Jul;18(7):2579-91 [17475772.001]
  • [Cites] EMBO J. 2007 Oct 31;26(21):4597-606 [17914456.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2504-11 [10811132.001]
  • [Cites] Cell. 2000 Jun 23;101(7):717-28 [10892743.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5401-4 [11034079.001]
  • [Cites] Cell. 2002 May 17;109(4):509-21 [12086607.001]
  • [Cites] Mol Biol Cell. 2002 Jul;13(7):2533-46 [12134088.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6278-88 [12414658.001]
  • [Cites] J Cell Biol. 2003 Feb 3;160(3):409-21 [12566431.001]
  • [Cites] J Cell Sci. 2004 Jul 15;117(Pt 16):3499-510 [15252126.001]
  • [Cites] J Cell Biol. 2004 Aug 30;166(5):697-708 [15337778.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:541-64 [14570581.001]
  • [Cites] FEBS Lett. 2004 Jan 2;556(1-3):211-5 [14706852.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):921-30 [14737122.001]
  • [Cites] Cell Motil Cytoskeleton. 2004 Apr;57(4):207-17 [14752805.001]
  • [Cites] Int J Cancer. 2004 May 10;109(6):909-18 [15027125.001]
  • [Cites] Neuron. 2004 Apr 8;42(1):37-49 [15066263.001]
  • [Cites] J Cell Biol. 2007 Nov 19;179(4):777-91 [18025308.001]
  • [Cites] Nat Cell Biol. 2007 Dec;9(12):1347-59 [18026093.001]
  • [Cites] J Cell Biol. 2007 Dec 17;179(6):1247-59 [18086920.001]
  • [Cites] Mol Cell. 2007 Dec 28;28(6):1071-82 [18158903.001]
  • [Cites] J Biol Chem. 2008 Apr 11;283(15):9814-9 [18283104.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7022-9 [15466195.001]
  • (PMID = 19081071.001).
  • [ISSN] 1878-1551
  • [Journal-full-title] Developmental cell
  • [ISO-abbreviation] Dev. Cell
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA100324; United States / NCI NIH HHS / CA / 1-U54-CA112967; United States / NIGMS NIH HHS / GM / GM38511; United States / NCI NIH HHS / CA / CA100324; United States / NIGMS NIH HHS / GM / GM038511-12; United States / NIGMS NIH HHS / GM / GM58801; United States / NCI NIH HHS / CA / U54 CA112967-04; United States / NCI NIH HHS / CA / CA112967-04; United States / NCI NIH HHS / CA / U54 CA112967; United States / NCI NIH HHS / CA / CA100324-01; United States / NIGMS NIH HHS / GM / R01 GM058801; United Kingdom / Cancer Research UK / / ; United States / NCI NIH HHS / CA / R01 CA113395; United States / NIGMS NIH HHS / GM / R01 GM038511; United States / NCI NIH HHS / CA / P01 CA100324-01; United States / NIGMS NIH HHS / GM / R01 GM058801-10; None / None / / U54 CA112967-03; United States / NIGMS NIH HHS / GM / R01 GM038511-12; United States / NCI NIH HHS / CA / U54 CA112967-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enah protein, human; 0 / Microfilament Proteins; 0 / Protein Isoforms; 62229-50-9 / Epidermal Growth Factor
  • [Other-IDs] NLM/ NIHMS87960; NLM/ PMC2637261
  •  go-up   go-down


28. Zhang Y, Li C, Fang X, Sun M: [Expression and clinical significance of matrix metalloproteinase-26 in non-small cell lung cancer.]. Zhongguo Fei Ai Za Zhi; 2008 Jun 20;11(3):420-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of matrix metalloproteinase-26 in non-small cell lung cancer.].
  • The aim of this study is to investigate the expression of MMP-26 protein in non-small cell lung cancer (NSCLC), and to analyze the correlations between MMP-26 and clinicopathological parameters.
  • METHODS: Seventy specimens of lung cancer, 30 of (para-cancer) normal lung tissues and 19 of pulmonary benign disease tissues were collected.
  • (1) The expression levels of MMP-26 protein in lung cancer tissues (64.3%) were significantly higher than that in paracancerous tissues (26.7%) and pulmonary benign disease tissues (31.3%) (P <0.01). (2) The expression levels of MMP-26 protein in lung cancer tissues were closely related to histological classification, grade of cell differentiation and TNM stages (P <0.05), but not related to age, sex, smoking history and tumor size (P >0.05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731946.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


29. Teppone M, Avakyan R: Extremely high-frequency therapy in oncology. J Altern Complement Med; 2010 Nov;16(11):1211-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: At the early stage of these studies, efficacy and safety of millimeter electromagnetic radiation (extremely high frequency [EHF]) was proved for various types of malignant tumors.
  • The majority of the further studies demonstrated the high efficacy and safety of millimeter wave radiation in treating patients suffering from both benign and malignant tumors.
  • RESULTS: Developments led to treatment on skin melanoma, cancer of the ear-nose-throat, bowel and breast cancer, cancer of the uterus, lung, and stomach, solid tumors, as well as lymphoma.
  • (3) prevention of metastases, relapses, and dissemination of the tumor;.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20973733.001).
  • [ISSN] 1557-7708
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


30. Massion PP, Caprioli RM: Proteomic strategies for the characterization and the early detection of lung cancer. J Thorac Oncol; 2006 Nov;1(9):1027-39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic strategies for the characterization and the early detection of lung cancer.
  • Biochemical techniques focused on changes in the proteome in benign and malignant conditions have been applied to the study of lung cancer.
  • Although relatively little information is currently available about the human lung proteome, the major goals of the analysis of lung cancer are to better understand tumor biology, to define early detection biomarkers and predictors of tumor behavior, and to identify potential new therapeutic targets.
  • In this review, we summarized the last 10 years of research in this area with emphasis on its application to the early detection of lung cancer.
  • Basic analytical tools, such as two-dimensional gel electrophoresis, mass spectrometry, and protein arrays, are described and placed in the context of lung cancer research.
  • [MeSH-major] Biomarkers, Tumor / blood. Early Diagnosis. Lung Neoplasms / diagnosis. Proteomics / methods
  • [MeSH-minor] Disease Progression. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Male. Mass Spectrometry. Neoplasm Proteins / analysis. Neoplasm Staging. Predictive Value of Tests. Prognosis. Protein Array Analysis. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409991.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102353
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Number-of-references] 95
  •  go-up   go-down


31. Hu WD, Liao MY, Chen JK: [Clinical analysis of solitary pulmonary nodule measuring less than 10 mm]. Ai Zheng; 2006 Feb;25(2):217-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Lung cancer is a malignant disease with high incidence and mortality, and its prognosis is to large degree determined by early diagnosis and treatment.
  • X-ray chest film and computed tomography (CT) are important means to discover and diagnose lung cancer.
  • The differences between benign and malignant lesions were compared.
  • Imaging features of SPN of lung cancer were summarized.
  • RESULTS: Of the 102 cases of SPN measuring less than 10 mm, 66 (64.7%) were benign lesions, 25 (24.5%) were primary lung cancer, and 11 (10.8%) were metastatic lung cancer.
  • The benign lesions included inflammatory pseudotumor, benign tumor, lung tuberculosis, and so on.
  • Primary lung cancers, including 6 advanced cases (stage IIA and higher stage), had several radiological features different from benign nodules, such as ill-defined margins, speculation, bronchus or vessel involvement.
  • Also, the enhanced CT value was higher in malignant nodules than in benign nodules except inflammation pseudotumor.
  • The SPNs of metastatic lung cancer had similar radiologic features to those of primary lung cancer.
  • CONCLUSION: SPNs measuring less than 10 mm are mainly composed of benign lung tumor and primary lung cancer.
  • [MeSH-major] Lung Neoplasms. Solitary Pulmonary Nodule
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma / secondary. Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / secondary. Female. Granuloma, Plasma Cell / pathology. Granuloma, Plasma Cell / radiography. Humans. Lung Diseases / pathology. Lung Diseases / radiography. Male. Middle Aged. Retrospective Studies. Smoking. Tomography, X-Ray Computed / methods. Tuberculosis, Pulmonary / pathology. Tuberculosis, Pulmonary / radiography

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16480590.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


32. Kurkcuoglu IC, Demircan S, Kurul IC, Demirag F: Endobronchial lipomatous hamartoma. Asian Cardiovasc Thorac Ann; 2005 Dec;13(4):372-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary hamartomas are the most common benign neoplasm of the lung, occurring in the parenchyma or sometimes within the bronchi.
  • Reported is a case of a 64-year-old male patient with an endobronchial tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304229.001).
  • [ISSN] 0218-4923
  • [Journal-full-title] Asian cardiovascular & thoracic annals
  • [ISO-abbreviation] Asian Cardiovasc Thorac Ann
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Kayser K, Hoshang SA, Metze K, Goldmann T, Vollmer E, Radziszowski D, Kosjerina Z, Mireskandari M, Kayser G: Texture- and object-related automated information analysis in histological still images of various organs. Anal Quant Cytol Histol; 2008 Dec;30(6):323-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS: A generalized algorithm was developed that permits the evaluation of diagnosis-associated image features obtained from hematoxylin-eosin-stained histopathologic slides.
  • The procedure was tested for screening of tumor tissue vs. tumor-free tissue in 1,442 cases of various organs.
  • Tissue samples studied include colon, lung, breast, pleura, stomach and thyroid.
  • RESULTS: The accuracy of automated crude classification was between 95% and 100% based upon a learning set of 10 cases per diagnosis class.
  • The algorithm can also distinguish between benign and malignant tumors of colon, between epithelial mesothelioma and pleural carcinomatosis or between different common pulmonary carcinomas.
  • It is a promising technique that can assist tissue-based diagnosis and be expanded to virtual slide evaluation.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19160697.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, Esposito D, Gillette WK, Hopkins RF 3rd, Hartley JL, Furihata M, Oishi S, Zhen W, Burke TR Jr, Linehan WM, Schmidt LS, Zbar B: Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A; 2006 Oct 17;103(42):15552-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Birt-Hogg-Dubé syndrome, a hamartoma disorder characterized by benign tumors of the hair follicle, lung cysts, and renal neoplasia, is caused by germ-line mutations in the BHD(FLCN) gene, which encodes a tumor-suppressor protein, folliculin (FLCN), with unknown function.
  • The tumor-suppressor proteins encoded by genes responsible for several other hamartoma syndromes, LKB1, TSC1/2, and PTEN, have been shown to be involved in the mammalian target of rapamycin (mTOR) signaling pathway.


35. Budhu AS, Zipser B, Forgues M, Ye QH, Sun Z, Wang XW: The molecular signature of metastases of human hepatocellular carcinoma. Oncology; 2005;69 Suppl 1:23-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The current metastasis paradigm suggests that the primary tumor starts off benign but over time slowly acquires changes that provide a few rare cells within the tumor the ability to metastasize.
  • Similar findings are also evident in primary cancers of the lung, breast, and prostate.
  • These findings imply that many of the metastasis-promoting genes are embedded in the primary tumors and that the ability to metastasize may be an inherent quality of the tumor from the beginning.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Liver Neoplasms / genetics. Neoplasm Metastasis / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Gene Expression Profiling. Humans. Models, Biological. Osteopontin. Prognosis. Sialoglycoproteins / analysis. Sialoglycoproteins / physiology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16210873.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 106441-73-0 / Osteopontin
  • [Number-of-references] 21
  •  go-up   go-down


36. Weissferdt A, Langman G: An intracapsular carcinoma ex pleomorphic adenoma with lung metastases composed exclusively of benign elements: histological evidence of a continuum between metastasizing pleomorphic adenoma and carcinoma ex pleomorphic adenoma. Pathol Res Pract; 2010 Jul 15;206(7):480-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An intracapsular carcinoma ex pleomorphic adenoma with lung metastases composed exclusively of benign elements: histological evidence of a continuum between metastasizing pleomorphic adenoma and carcinoma ex pleomorphic adenoma.
  • Malignant mixed tumors of the salivary glands, encompassing carcinoma ex pleomorphic adenoma (ca ex PA), carcinosarcoma and metastasizing pleomorphic adenoma (mPA), are rare neoplasms.
  • When the malignant component does not breach the capsule of the parent PA, the lesion is termed intracapsular ca ex PA, a neoplasm which is thought to have no metastatic potential.
  • Metastatic deposits of ca ex PA are composed exclusively of malignant elements or mixed benign and malignant components.
  • We describe the case of a 62-year-old female with an intracapsular ca ex PA of the buccal mucosa with subsequent metastases to the lung.
  • The metastatic deposits resembled benign PA with no histological evidence of malignancy.
  • This pattern of spread is described with mPA, an entity that caused controversy in the past regarding its exact classification as a benign or malignant tumor.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Lung Neoplasms / secondary. Mouth Mucosa / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19665316.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


37. Feng F, Nie G, Wu Y, Wu Y: [Comparison and analysis of three classifying models for discrimination of lung cancer established by 6 tumor markers]. Wei Sheng Yan Jiu; 2009 Jul;38(4):429-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison and analysis of three classifying models for discrimination of lung cancer established by 6 tumor markers].
  • OBJECTIVE: To distinguish lung cancer by detecting 6 tumor markers in serum and establishing three classifying models of artificial neural networks (ANN), decision tree (CART), Fisher discrimination analysis, and to compare the differences among three models.
  • METHODS: The levels of serum CEA, gastrin, NSE, sialic acid (SA), Cu/ Zn, Ca in 50 healthy individuals, 40 patients with lung benign disease and 50 patients with lung cancers were detected by means of radioimmunology, spectrophotometry, atomic absorption spectrophotometry, respectively, and then developed ANN, CART and Fisher discrimination analysis models.
  • CONCLUSION: The effects of ANN, CART models established by 6 tumor markers were better than that of Fisher discrimination analysis in discrimination of lung cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Decision Trees. Discriminant Analysis. Lung Neoplasms / diagnosis. Neural Networks (Computer)
  • [MeSH-minor] Carcinoembryonic Antigen / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Non-Small-Cell Lung / diagnosis. Diagnosis, Differential. Gastrins / blood. Humans. N-Acetylneuraminic Acid / blood. ROC Curve. Sensitivity and Specificity. Small Cell Lung Carcinoma / blood. Small Cell Lung Carcinoma / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19689074.001).
  • [ISSN] 1000-8020
  • [Journal-full-title] Wei sheng yan jiu = Journal of hygiene research
  • [ISO-abbreviation] Wei Sheng Yan Jiu
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Gastrins; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


38. Zhang PJ, Gao HG, Pasha TL, Litzky L, Livolsi VA: TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems. Int J Gynecol Pathol; 2009 Jan;28(1):10-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems.
  • Thyroid transcription factor-1 (TTF-1) is a 38-kd homeodomain containing DNA-binding protein, identified in thyroid and lung as a regulator of thyroid-specific genes and surfactant and Clara cell secretory protein gene expression.
  • TTF-1 has been used as a reliable lineage marker for lung adenocarcinoma and thyroid carcinoma in surgical pathology.
  • We evaluated TTF-1 expression with 3 primary different antibodies (8G7G3/1, SPT24, and BGX-397A) and 2 secondary automated detection systems (Envision+/Dako autostainer versus Refine/Bond Max) in 104 ovarian and endometrial tumors on routine surgical specimens and 108 ovarian tumors on tissue microarray (TMA) specimens.
  • By using SPT24/Refine/Bond Max, TTF-1 reactivity could be detected in all major histologic subtypes of gynecologic tumors and up to 26% of all cases tested on routine surgical specimens and 6.4% on TMA.
  • TTF-1 was most frequently detected in uterine malignant mixed Müllerian tumor (82%), more common in uterine tumors than ovarian tumors, and more common in surgical specimen than TMA.
  • When present, tumor cells can be rarely positive or diffusely positive for TTF-1 reactivity.
  • In addition to malignant tumors, TTF-1 was also detected in benign tumors and benign tubal and endometrial epithelia.
  • TTF 1 immunostaining has the potential to misguide a pathologist to conclude an ovarian or endometrial tumor being a lung metastasis.
  • However, the role of TTF-1 in female genital tract and its tumors is unknown.
  • [MeSH-major] Biomarkers, Tumor / analysis. Endometrial Neoplasms / metabolism. Immunohistochemistry / methods. Nuclear Proteins / biosynthesis. Ovarian Neoplasms / metabolism. Transcription Factors / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047914.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


39. Bossert T, Walther T, Vondrys D, Gummert JF, Kostelka M, Mohr FW: Cardiac fibroma as an inherited manifestation of nevoid basal-cell carcinoma syndrome. Tex Heart Inst J; 2006;33(1):88-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Echocardiography revealed a left ventricular tumor.
  • The tumor was resected through a left ventriculotomy, and the left ventricle was reconstructed after a partial ventriculectomy Histologic investigation showed a completely resected benign fibroma.

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2001 Apr;71(4):1354-6 [11308193.001]
  • [Cites] Ann Thorac Surg. 2003 Apr;75(4):1306-8 [12683582.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1986 Jul;112(7):773-5 [3707741.001]
  • [Cites] Medicine (Baltimore). 1987 Mar;66(2):98-113 [3547011.001]
  • [Cites] Am Heart J. 1997 Dec;134(6):1107-14 [9424072.001]
  • [Cites] Pediatr Cardiol. 1991 Apr;12(2):118-20 [1866331.001]
  • [Cites] J Med Genet. 1993 Jun;30(6):460-4 [8326488.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Nov;108(5):862-70 [7967668.001]
  • [Cites] J Heart Lung Transplant. 1995 Mar-Apr;14(2):382-6 [7779860.001]
  • [Cites] Thorac Cardiovasc Surg. 1990 Aug;38 Suppl 2:176-82 [2237899.001]
  • (PMID = 16572881.001).
  • [ISSN] 0730-2347
  • [Journal-full-title] Texas Heart Institute journal
  • [ISO-abbreviation] Tex Heart Inst J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1413607
  •  go-up   go-down


40. Witschi H, Espiritu I, Maronpot RR: Lung tumors in 2 year old strain A/J mice exposed for 6 months to tobacco smoke. Cancer Lett; 2006 Sep 8;241(1):64-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung tumors in 2 year old strain A/J mice exposed for 6 months to tobacco smoke.
  • Lung tumor multiplicities in the smoke exposed animals were 1.8+/-0.2 versus 0.9+/-0.2 in controls.
  • In animals kept beyond the age of 12 months, lung tumor multiplicities increased in both groups, but remained at all times twice the control values in the smoke exposed animals compared to controls (4.3+/-0.7 vs. 2.1+/-0.5 tumors per lung in 24 months old animals).
  • Histopathology showed that, in 2 year old animals, still about 80% of tumors were of benign nature.
  • No tumors were found in the nasal passages.
  • It was concluded that tobacco smoke exposure not simply accelerates the development of lesions that eventually would have developed spontaneously, but induced de novo formation of lung tumors in A/J mice.
  • [MeSH-major] Lung Neoplasms / etiology. Smoke / adverse effects. Tobacco

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16290922.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA96217; United States / NIEHS NIH HHS / ES / ES05707; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Smoke
  •  go-up   go-down


41. Zhong D, Guo L, de Aguirre I, Liu X, Lamb N, Sun SY, Gal AA, Vertino PM, Zhou W: LKB1 mutation in large cell carcinoma of the lung. Lung Cancer; 2006 Sep;53(3):285-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LKB1 mutation in large cell carcinoma of the lung.
  • Germline inactivation of LKB1 is responsible for Peutz-Jeghers syndrome, an autosomal dominant disorder characterized by benign hamartomas of the GI tract and an increased predisposition to certain cancers, including lung.
  • Acquired mutations in LKB1 are rarely observed in most sporadic tumor types except for adenocarcinomas of the lung where up to 50% harbor inactivating mutations.
  • In this study, we focused on LKB1 mutations in lung cancer cell lines originating from large cell carcinomas.
  • Of the four cell lines and six primary tumors of large cell lung carcinoma origin that have been evaluated in this and other studies, LKB1 mutations have been found in three cases.
  • These results suggest that, in addition to adenocarcinomas, acquired loss of function mutations in LKB1 may also be frequently involved in the pathogenesis of large cell lung carcinomas.
  • [MeSH-major] Carcinoma, Large Cell / metabolism. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. Protein-Serine-Threonine Kinases / genetics. Protein-Serine-Threonine Kinases / physiology
  • [MeSH-minor] AMP-Activated Protein Kinases. Alleles. Cell Line, Tumor. DNA, Complementary / metabolism. Gene Deletion. Green Fluorescent Proteins / metabolism. Homozygote. Humans. Loss of Heterozygosity. Multienzyme Complexes / metabolism. Mutation. Phosphorylation. Protein Structure, Tertiary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16822578.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA077337
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Multienzyme Complexes; 147336-22-9 / Green Fluorescent Proteins; EC 2.7.1.- / STK11 protein, human; EC 2.7.11.1 / AMP-Activated Protein Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


42. Tsunezuka Y, Shimizu Y, Tanaka N, Takayanagi T, Kawano M: Positron emission tomography in relation to Noguchi's classification for diagnosis of peripheral non-small-cell lung cancer 2 cm or less in size. World J Surg; 2007 Feb;31(2):314-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography in relation to Noguchi's classification for diagnosis of peripheral non-small-cell lung cancer 2 cm or less in size.
  • BACKGROUND: F-18 fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) scanning has become a critically important tool in diagnosis and management of non-small-cell lung cancer.
  • However, the effectiveness of (18)F-FDG-PET as a diagnostic tool for small-sized lung cancer is controversial.
  • The purpose of this study was to examine the accuracy of( 18)F-FDG-PET in relation to Noguchi's classification in the diagnosis of small peripheral non-small-cell lung cancer.
  • METHODS: Between January 2003 and April 2006, 150 patients with peripheral lung lesions who were undergoing chest computed tomography (CT),( 18)F-FDG-PET, and operation were analyzed.
  • RESULTS: Eighty-three patients had malignant lesions, and 67 patients had benign lesions.
  • In 37 patients with peripheral lung cancer measuring 2.0 cm or less in the greatest diameter, the sensitivity was 51.4% and the specificity was 51.9%.
  • CONCLUSION: The accuracy of( 18)F-FDG-PET is generally low in distinguishing malignancy from benign lesions in small lesions (<2.0-cm diameter).
  • The significance of PET as a diagnostic tool is small, especially when the tumor has a ground-glass component at a high rate.
  • The sensitivity of PET is high in small invasive carcinomas without a BAC component, but it is difficult to distinguish carcinoma from benign tumor from its image.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnostic imaging. Carcinoma, Non-Small-Cell Lung / diagnostic imaging. Fluorodeoxyglucose F18. Lung Neoplasms / diagnostic imaging. Mixed Tumor, Malignant / diagnostic imaging. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 2002 Aug;124(2):278-84 [12167787.001]
  • [Cites] Respiration. 2003 Sep-Oct;70(5):500-6 [14665776.001]
  • [Cites] Ann Nucl Med. 2004 Feb;18(1):23-8 [15072180.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8396-405 [16293870.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1166-73 [12192561.001]
  • [Cites] Lung Cancer. 2003 Dec;42(3):303-10 [14644518.001]
  • [Cites] Chest. 2006 Feb;129(2):393-401 [16478857.001]
  • [Cites] Ann Thorac Surg. 2004 Sep;78(3):1017-23; discussion 1017-23 [15337041.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):426-31 [16513611.001]
  • [Cites] Ann Thorac Surg. 2001 Mar;71(3):956-60; discussion 961 [11269480.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1075-84 [9508193.001]
  • (PMID = 17219276.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


43. Ponti G, Luppi G, Martorana D, Rossi G, Losi L, Bertolini F, Sartori G, Pellacani G, Seidenari S, Boni E, Neri TM, Silini E, Tamburini E, Maiorana A, Conte PF: Gastrointestinal stromal tumor and other primary metachronous or synchronous neoplasms as a suspicion criterion for syndromic setting. Oncol Rep; 2010 Feb;23(2):437-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumor and other primary metachronous or synchronous neoplasms as a suspicion criterion for syndromic setting.
  • Gastrointestinal stromal tumors (GISTs) may be sporadic or inherited.
  • The present study was designed to analyze the synchronous and metachronous tumors developed among GIST patients assessed by our institution for GIST Syndrome setting recognition.
  • The development of GIST associated with other neoplasms is common and diagnosis of peculiar benign associated-neoplasms warrants the search for familial cancer susceptibility.
  • In particular, syndromic or familial settings have to be suspected in the presence of neurofibroma or lung chordoma in C-KIT and PDGFRA negative GIST patients.
  • [MeSH-major] Gastrointestinal Stromal Tumors / diagnosis. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Adult. Aged. Carney Complex / complications. Carney Complex / genetics. DNA Mutational Analysis / methods. Diagnosis, Differential. Female. Genes, Neurofibromatosis 1. Humans. Male. Middle Aged. Neurofibromatoses / complications. Neurofibromatoses / diagnosis. Neurofibromatoses / genetics. Pedigree. Retrospective Studies. Syndrome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043105.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


44. Cetani F, Ambrogini E, Viacava P, Pardi E, Fanelli G, Naccarato AG, Borsari S, Lemmi M, Berti P, Miccoli P, Pinchera A, Marcocci C: Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol; 2007 May;156(5):547-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
  • The aim of our study was to extend parafibromin studies in a series of benign and malignant parathyroid tumors and cross-validate the results of immunohistochemistry with those of HRPT2 analysis.
  • DESIGN AND PATIENTS: We performed parafibromin and cyclin D1 immunostaining and HRPT2 gene analysis using loss of heterozygosity studies and sequencing analysis in parathyroid specimens from 11 patients with carcinoma (eleven primary tumors, one skin, and four lung metastases), 22 with sporadic adenomas, and 4 with atypical adenomas.
  • In clinical practice, these tests could be particularly useful in the subset of parathyroid tumors with equivocal histological examination.

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17468190.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDC73 protein, human; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1
  •  go-up   go-down


45. Hannah CD, Oliver DH, Liu J: Fine needle aspiration biopsy and immunostaining findings in an aggressive inflammatory myofibroblastic tumor of the lung: a case report. Acta Cytol; 2007 Mar-Apr;51(2):239-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration biopsy and immunostaining findings in an aggressive inflammatory myofibroblastic tumor of the lung: a case report.
  • BACKGROUND: Inflammatory myofibroblastic tumors (IMTs) can vary from benign pseudosarcomatous tumors to low grade sarcomas.
  • To date, fine needle aspiration (FNA) findings of lung IMTs, especially in the aggressive form, have not been fully described.
  • CASE: A 22-year-old man first presented with a left lung mass and 4.5 years later with a recurrent mass.
  • Preoperative computed tomography-guided FNA was performed on both tumors.
  • Thirty percent of the tumor cells were positive for p53.
  • Histologic examination of the surgically resected initial and recurrent masses confirmed the diagnosis of lMT.
  • Immunohistochemical studies can assist in the diagnosis by excluding other spindle cell lesions.
  • [MeSH-major] Inflammation / pathology. Lung / pathology. Lung Neoplasms / pathology. Neoplasms, Muscle Tissue / pathology
  • [MeSH-minor] Actins / analysis. Actins / metabolism. Adult. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Cell Shape / physiology. Diagnosis, Differential. Humans. Immunohistochemistry / methods. Lymphocytes / pathology. Male. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / physiopathology. Plasma Cells / pathology. Predictive Value of Tests. Reoperation. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / metabolism. Vimentin / analysis. Vimentin / metabolism

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17425213.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; 0 / Vimentin
  •  go-up   go-down


46. Moschos C, Porfiridis I, Psallidas I, Kollintza A, Stathopoulos GT, Papiris SA, Roussos C, Kalomenidis I: Osteopontin is upregulated in malignant and inflammatory pleural effusions. Respirology; 2009 Jul;14(5):716-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with malignant pleural effusions had higher PF and lower serum OPN concentrations than those with benign disease.
  • [MeSH-major] Lung Diseases / metabolism. Lung Neoplasms / metabolism. Osteopontin / metabolism. Pleural Effusion / metabolism. Pleural Effusion, Malignant / metabolism. Pleural Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / metabolism. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Pneumonia / complications. Pneumonia / diagnosis. Pneumonia / metabolism. Prospective Studies. Tuberculosis / complications. Tuberculosis / diagnosis. Tuberculosis / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19476604.001).
  • [ISSN] 1440-1843
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin
  •  go-up   go-down


47. Dhillon MS, Prasad P: Multicentric giant cell tumour of bone. Acta Orthop Belg; 2007 Jun;73(3):289-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric giant cell tumour of bone.
  • Although giant cell tumour (GCT) is seen quite frequently, multicentric giant cell tumour (MCGCT) is a rare entity occurring in less than 1% of patients with GCT.
  • The pathogenesis of MCGCT is debated; various mechanisms have been postulated, including contiguous spread, iatrogenic tumour cell seeding, benign metastasis, malignant transformation and de novo formation.
  • Four lung metastases and two histologically malignant lesions were found.
  • [MeSH-major] Bone Neoplasms. Giant Cell Tumor of Bone
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17715717.001).
  • [ISSN] 0001-6462
  • [Journal-full-title] Acta orthopaedica Belgica
  • [ISO-abbreviation] Acta Orthop Belg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 77
  •  go-up   go-down


48. Bernabé DG, Veronese LA, Miyahara GI, Conrado-Neto S, Biasoli ER: Gingival metastasis from salivary duct carcinoma of the parotid gland. J Periodontol; 2008 Apr;79(4):748-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The intraoral examination revealed a reddish, superficially ulcerated nodular lesion ( approximately 2 cm in diameter) on the right mandibular buccal attached gingiva, and the clinical aspect was that of a benign reactive lesion.
  • RESULTS: The analysis of the histopathologic sections of the gingival lesion revealed histomorphologic characteristics very similar to those of the primary parotid gland tumor.
  • The definitive diagnosis was gingival metastasis from a salivary duct carcinoma of the parotid gland.
  • The patient died of complications of a pulmonary metastasis 1 month after the diagnosis of the oral metastatic lesion.
  • An accurate and timely diagnosis is crucial to establish proper and immediate treatment of the metastatic tumor and possibly identify an occult primary malignant neoplasia.
  • [MeSH-minor] Aged. Fatal Outcome. Humans. Lung Neoplasms / secondary. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18380570.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Szczepulska-Wójcik E, Langfort R, Roszkowski-Sliz K: [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation]. Pneumonol Alergol Pol; 2007;75(1):57-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
  • INTRODUCTION: Histopathological diagnosis of malignant mesothelioma (MM) and differentiating it from tumors infiltrating the pleura is very difficult.
  • Distinguishing benign reactive mesothelial cell proliferation from MM also presents problems.
  • The objective of this study was to evaluate the significance of selected immunohistochemical stains in differentiating MM from non-small cell lung cancers infiltrating the pleura and from benign reactive mesothelial cell proliferation.
  • MATERIAL AND METHODS: The material encompassed 86 cases of MM, 54 cases of NSCLC infiltrating the pleura, and 43 cases of benign reactive mesothelial cell proliferation.
  • Non-small cell lung cancers infiltrating the pleura: Coexpression of cytokeratin and vimentin was found in 17.6% of the cases, positive staining of membranes for EMA, in 13% cases.
  • Benign reactive mesothelial cell proliferation: Protein p53 was present in 9.3% of cases, whereas no positive staining for EMA was found.
  • In the diagnosis of spindle-cell pleural tumors and the fibrous form of MM and benign reactive mesothelial cell proliferation , markers of mesothelial cells are noncontributory.
  • Immunohistochemical staining fails to identify a reactive process, but a diffuse, positive stain for EMA and the presence of protein p53 support the diagnosis of MM.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / analysis. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / pathology. Mesothelioma / pathology. Neoplasm Proteins / analysis. Neoplasms, Mesothelial / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / analysis. Diagnosis, Differential. Epithelium / chemistry. Epithelium / pathology. Female. Humans. Hyperplasia / pathology. Immunohistochemistry. Lung / chemistry. Lung / pathology. Male. Middle Aged. Pleura / chemistry. Pleura / pathology. Pleural Effusion / chemistry. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541913.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


51. Glaab R, Turina M, Achermann E, Maurer R, Went P, Schöb O: [Alveolar adenoma--a rare pulmonary mass: case report and review of the literature]. Zentralbl Chir; 2009 Sep;134(5):478-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Definitive histology following thoracoscopic wedge resection showed the distinctive findings of an alveolar adenoma, a very rare benign tumour of the lung of unknown histogenesis.
  • Its histological features, the benign proliferation of alveolar epithelium and septal mesenchyme, allow for its distinction from other benign lesions of the lung.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma, Bronchogenic / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Hemoptysis / etiology. Humans. Lung / pathology. Male. Middle Aged. Phlebography. Pneumonectomy. Thoracoscopy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag Stuttgart-New York.
  • (PMID = 19757349.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 5
  •  go-up   go-down


52. Rodriguez FJ, Aubry MC, Tazelaar HD, Slezak J, Carney JA: Pulmonary chondroma: a tumor associated with Carney triad and different from pulmonary hamartoma. Am J Surg Pathol; 2007 Dec;31(12):1844-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary chondroma: a tumor associated with Carney triad and different from pulmonary hamartoma.
  • The Carney triad is the clinical association of gastric stromal sarcomas, pulmonary cartilaginous tumors, and extra-adrenal paragangliomas.
  • The pulmonary tumors are its second commonest component and have been misinterpreted clinically and pathologically as metastases from the gastric tumors and pulmonary cartilaginous hamartomas, respectively.
  • Forty-two patients with pulmonary cartilaginous tumors as a component of Carney triad were identified.
  • A subgroup of 41 tumors from the latter was compared with those in a group of pulmonary cartilaginous hamartomas.
  • Their pulmonary neoplasm(s) were usually asymptomatic, often multiple, well circumscribed, medium-sized (mean diameter=2.8 cm), and composed almost exclusively of cartilage and bone surrounded by a fibrous pseudocapsule.
  • None of the tumors metastasized or was fatal.
  • The pulmonary neoplasms in the Carney triad are well-differentiated benign cartilaginous tumors that are best designated as chondromas.
  • [MeSH-major] Chondroma / pathology. Hamartoma / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Gastrointestinal Stromal Tumors / pathology. Humans. Male. Middle Aged. Paraganglioma, Extra-Adrenal / pathology

  • Genetic Alliance. consumer health - Chondroma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043038.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Langenfeld EM, Bojnowski J, Perone J, Langenfeld J: Expression of bone morphogenetic proteins in human lung carcinomas. Ann Thorac Surg; 2005 Sep;80(3):1028-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of bone morphogenetic proteins in human lung carcinomas.
  • Bone morphogenetic protein-2 (BMP-2) was recently shown to be expressed in a small sample of lung carcinomas.
  • Studies have suggested that BMP-2 may enhance tumor growth.
  • The present study examined which BMP family members are expressed in non-small cell lung carcinomas (NSCLC).
  • Furthermore, the frequency of BMP-2 overexpression and the types of lung carcinomas expressing BMP-2 were determined.
  • Samples included metastatic NSCLC, benign lung tumors, adenocarcinoma, squamous cell carcinoma, bronchioloalveolar, and neuroendocrine carcinomas.
  • Paired normal lung tissues served as the controls.
  • The BMP-2 was expressed in 41 of 42 NSCLC with minimal expression in normal lung tissue; BMP-2 was expressed 17 fold higher than that of normal lung tissue.
  • The BMP-2 was not significantly expressed in benign lung tumors.
  • The BMP-2 is overexpressed in the majority of human lung carcinomas independent of cell type.
  • [MeSH-major] Bone Morphogenetic Proteins / metabolism. Lung Neoplasms / genetics. Lung Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Bone Morphogenetic Protein 2. Bone Morphogenetic Protein 4. Bone Morphogenetic Protein 6. Bone Morphogenetic Protein 7. Carcinoma, Neuroendocrine / genetics. Carcinoma, Neuroendocrine / metabolism. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Growth Differentiation Factor 5. Humans. Transforming Growth Factor beta / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2005 Sep;80(3):1032 [16122480.001]
  • (PMID = 16122479.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA91919-01A1
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BMP2 protein, human; 0 / BMP4 protein, human; 0 / BMP6 protein, human; 0 / BMP7 protein, human; 0 / Bone Morphogenetic Protein 2; 0 / Bone Morphogenetic Protein 4; 0 / Bone Morphogenetic Protein 6; 0 / Bone Morphogenetic Protein 7; 0 / Bone Morphogenetic Proteins; 0 / GDF5 protein, human; 0 / Growth Differentiation Factor 5; 0 / Transforming Growth Factor beta
  •  go-up   go-down


54. Yang YJ, Cheng DY, Fang X, Li XX: [The clinical diagnosis value of fibro-optic bronchoscope examination combined with tumor marker determination to lung cancer]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Mar;38(2):312-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical diagnosis value of fibro-optic bronchoscope examination combined with tumor marker determination to lung cancer].
  • OBJECTIVE: To investigate the diagnosis value of fibro-optic-bronchoscope combined with tumor maker determination to lung cancer.
  • METHODS: By fibro-optic bronchoscope (FB) and electrochemiluminescence (ECL) examinations, 98 cases with lung cancer and 88 cases with benign lung disease were studied for calculating the detectable sensitivity and specificity to lung cancer, then further for evaluating the clinical value of FB examination combined with detection of tumor marker in serum/pleural fluid of patients with lung cancer.
  • Results In patients with lung cancer, the serum levels of CEA, CA125 and CYFRA21-1 were (46.34 +/- 18.28) ng/mL, (83.34 +/- 33.26) U/mL and (25.67 +/- 10.32) ng/mL respectively, which were higher than those in patients with benign lung diseases.
  • The serum levels of above three tumor markers in patients with lung cancer all were significantly higher than those in patients with benign lung diseases (P < 0.05).
  • In the 36 specimens of pleural fluid, three tumor markers were higher than those in the corresponding serum samples.
  • The detectable sensitivity of each tumor marker in pleural fluid was higher than that in serum.
  • The sensitivity, specificity and overall accuracy of CEA in lung cancer were 37.5%, 87.5% and 63.6% respectively, of CA125 were 67.7%, 40.9% and 54.9%; of CYFRA21-1 were 56.3%, 81.8% and 68.5%; of FB were 60.4%, 100.0% and 79.4% respectively.
  • The sensitivity, specificity or overall accuracy of fibro-optic bronchoscope combined with tumor marker (TM) examination to diagnosis of lung cancer was 90.6%, 92.0% or 91.3% respectively.
  • CONCLUSION: The FB examination is valuable in diagnosing lung cancer, and by combined with TM determination, can further improve the accuracy to diagnosis of lung cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Bronchoscopy / methods. Lung Neoplasms / blood. Lung Neoplasms / diagnosis. Optical Fibers

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17441358.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


55. Pelosi G, Rodriguez J, Viale G, Rosai J: Salivary gland-type tumors with myoepithelial differentiation arising in pulmonary hamartoma: report of 2 cases of a hitherto unrecognized association. Am J Surg Pathol; 2006 Mar;30(3):375-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland-type tumors with myoepithelial differentiation arising in pulmonary hamartoma: report of 2 cases of a hitherto unrecognized association.
  • Reported is a hitherto unrecognized association of pulmonary hamartomas with salivary gland-type tumors showing myoepithelial differentiation, namely, a case of myoepithelioma arising in a otherwise classic hamartoma with cartilage predominance, and a case of malignant mixed tumor arising in a predominantly fibrous hamartoma resembling müllerian adenofibroma.
  • The tumors occurred in middle-aged female patients of 35 and 44 years, respectively, and presented as 7 cm (treated with lobectomy) and 13 cm (treated with pneumonectomy) masses of the right upper lobe showing a short clinical history of cough, dyspnea, and wheezing.
  • The myoepithelioma patient was well with no signs of recurrent disease at 6-month clinical control, but she was then lost to follow-up; the malignant mixed tumor patient is alive and well after 6 months since operation.
  • Both tumors presented with morphologic and immunohistochemical features of myoepithelial cells, and we interpret them as being derived from a myoepithelial-like stromal cell population found within the hamartomatous areas, which is also consistently detected in classic pulmonary hamartoma.
  • The lack of individual cell necrosis, mitotic activity, cell atypia, and pulmonary parenchyma infiltration supported a diagnosis of benign or unproven malignant potential tumor for the myoepithelioma, whereas the reverse held true for the other tumor in which the diagnosis of malignant mixed tumor of the lung was rendered.
  • Their main importance of recognizing this association lies in separating these tumors histologically from other monophasic or biphasic tumors, either primary or secondary, such as pulmonary sarcomatoid carcinomas or true sarcomas, and metastatic salivary gland tumors, spindle cell carcinomas, melanomas, and soft tissue and visceral sarcomas.
  • [MeSH-major] Hamartoma / pathology. Lung Neoplasms / pathology. Mixed Tumor, Malignant / pathology. Myoepithelioma / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor. Biopsy, Needle. Cell Transformation, Neoplastic. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lung Diseases / metabolism. Lung Diseases / pathology. Lung Diseases / surgery. Salivary Glands / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538059.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


56. Ferlito A, Devaney KO, Rinaldo A: Primary carcinoid tumor of the middle ear: a potentially metastasizing tumor. Acta Otolaryngol; 2006 Mar;126(3):228-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoid tumor of the middle ear: a potentially metastasizing tumor.
  • The concept of a carcinoid tumor in the gastrointestinal tract and lung is well established; less often, patients develop carcinoid tumors in the head and neck region.
  • One particularly uncommon site of origin of carcinoid tumors in the head and neck area is the middle ear.
  • Middle ear carcinoids have previously been approached as benign entities, lacking any capacity for metastasizing.
  • A critical review of the literature, however, disclosed a small number of cases in which middle ear carcinoid tumors have given rise to regional (cervical node) metastases.
  • This in turn suggests that, as is the case with pulmonary carcinoid tumors, middle ear carcinoids should be thought of as low-grade malignancies which, while relatively slow-growing, nevertheless possess a limited capacity for spreading to regional lymph nodes.
  • To date, distant metastases have not been associated with middle ear carcinoid tumors.
  • [MeSH-major] Carcinoid Tumor / secondary. Ear Neoplasms / pathology. Ear, Middle. Lymphatic Metastasis / pathology. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Biopsy, Needle. Female. Humans. Immunohistochemistry. Male. Neoplasm Staging. Prognosis. Risk Assessment. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618645.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 21
  •  go-up   go-down


57. Kim JM, Hwang SH, Song EJ, Lee SY, Kim YD, Lee CH, Lee MK, Chang CL, Lee EY: [Comparative quantification of plasma hnRNP B1 mRNA in non-small cell lung cancer patients by real-time PCR]. Korean J Lab Med; 2009 Jun;29(3):249-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative quantification of plasma hnRNP B1 mRNA in non-small cell lung cancer patients by real-time PCR].
  • Heterogeneous nuclear ribonucleoprotein (hnRNP) B1, a nuclear core complex, is overexpressed in early stage lung cancer.
  • We intended to evaluate the usefulness of plasma hnRNP B1 mRNA in differentiating non-small cell lung cancer (NSCLC) from other benign lung diseases, especially pulmonary tuberculosis, which is highly prevalent in Korea and often difficult to distinguish from lung cancer.
  • METHODS: Plasma RNA was extracted from 30 patients with NSCLC, 30 patients with benign lung diseases including pulmonary tuberculosis, and 10 healthy controls.
  • Normalized 2-DeltaDeltaCt of plasma hnRPN B1 mRNA was 62.2 (95%Cl, 6.4-210.1) in NSCLC patients and 2.7 (95%Cl, 0.5-13.6) in benign lung disease patients (P<0.001, Mann-Whitney U test).
  • CONCLUSIONS: Plasma hnRNP B1 mRNA was significantly increased in patients with lung cancer compared with that in patients with other benign lung diseases.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Heterogeneous-Nuclear Ribonucleoprotein Group A-B / blood. Lung Neoplasms / genetics. RNA, Messenger / blood
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. Female. Humans. Lung Diseases / blood. Lung Diseases / genetics. Male. Middle Aged. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19571624.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Heterogeneous-Nuclear Ribonucleoprotein Group A-B; 0 / RNA, Messenger; 0 / hnRNP A2
  •  go-up   go-down


58. Deniz H, Kibar Y, Güldür ME, Bakir K: Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations? Pathol Res Pract; 2009;205(11):749-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
  • Since pulmonary adenocarcinomas, malignant mesotheliomas (MM), and sometimes benign mesothelial proliferations show a great histomorphological resemblance to each other, an immunohistochemical panel is usually necessary for differential diagnosis.
  • The aim of this study is to compare D2-40 immunostaining in MM, pulmonary adenocarcinoma, and benign mesothelial proliferations.
  • In this retrospective study, D2-40 immunostaining was investigated in 37 cases of MM, 36 cases of pulmonary adenocarcinoma, and 31 cases of benign mesothelial proliferation.
  • The diagnosis of MM had previously been confirmed by a panel including calretinin, CK5/6, and CEA.
  • Predominantly membranous immunoreactivity was observed in 51% of MMs and in 55% of benign mesothelial proliferations.
  • We believe that D2-40 may be helpful in the differential diagnosis of MM from pleural involvement of pulmonary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antibodies, Monoclonal. Lung / metabolism. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis. Solitary Fibrous Tumor, Pleural / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Biomarkers, Tumor / metabolism. Chi-Square Distribution. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Pleura / metabolism. Pleural Neoplasms / diagnosis. Pleural Neoplasms / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19573998.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40
  •  go-up   go-down


59. Zhang Y, Miao Y, Yi J, Wang R, Chen L: Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer. Clin Lung Cancer; 2010 Jul 1;11(4):264-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.
  • BACKGROUND: Deleted in lung and esophageal cancer 1 (DLEC1) gene was a new candidate tumor suppressor gene.
  • We determined the expression level and methylation status of DLEC1 in non-small-cell lung cancer (NSCLC), and the DLEC1 methylation in plasma DNA as a biomarker for NSCLC was further evaluated.
  • PATIENTS AND METHODS: The study population enrolled 78 paired NSCLC specimens and adjacent normal tissues and 25 benign pulmonary lesions.
  • RESULTS: Hypermethylation of DLEC1 was found in 41% (32/78) of NSCLC tissues, which was significantly higher than that of adjacent normal tissues (3.8%; 3/78) and benign lesions (0/25; P < .001).
  • Methylated DLEC1 was detected in 35.9% (28/78) of plasma samples from NSCLC patients and only 2% (1/50) in cancer-free controls, and the concordance of DLEC1 methylation status in plasmas and corresponding tumor tissues was good.
  • CONCLUSION: DLEC1 is silenced by promoter methylation in NSCLC specimens and is widely expressed in adjacent normal tissues and benign control samples.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. DNA Methylation. Epigenesis, Genetic. Lung Neoplasms / genetics. Promoter Regions, Genetic / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Case-Control Studies. Female. Humans. Immunoenzyme Techniques. Lung / metabolism. Lung / pathology. Male. Middle Aged. Prognosis. Survival Rate. Tumor Cells, Cultured


60. Zhang XM, Shen CY, Li W, Zhang XM: [Surgical treatment of tumor invading important vessel]. Zhonghua Wai Ke Za Zhi; 2007 Aug 1;45(15):1044-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of tumor invading important vessel].
  • OBJECTIVE: To sum up preliminary experience of successful resection of tumor involving important vessel in 77 cases.
  • The tumor involving thoraco-abdominal cavity was in one case with malignant neuroblastoma.
  • The tumor from retro-peritoneum invaded into the whole inferior vena cava (IVC), and into two-thirds of the right atrium.
  • Tumor located in thoracic cavity were in 13 cases including IVC leiomyosarcoma in 2 cases, thymic carcinoma in 3 cases, malignant thymoma in 4 cases, malignant seminoma of superior mediastinum in 1 case, malignant lymphoma in 1 case, lung cancer in 2 cases.
  • The tumor located in abdominal cavity were in 24 cases including renal carcinoma with tumor thrombi in 11 cases, inflammatory pseudotumor of retro-peritoneum in 4 cases, malignant fibrous histiocytoma of retro-peritoneum in 1 case, non-Hodgkin's disease of retro-peritoneum in 1 case, lymph metastasis of retro-peritoneum in 2 cases, paraganglion tumor of the right adrenal gland in 1 case, ampullary carcinoma in 1 case, leiomyosarcoma of abdominal IVC in 1 case, leiomyosarcoma of pelvic cavity and IVC in 1 cases, fibrosarcoma of pelvic cavity in 1 case.
  • Tumor located in four extremities in 6 cases including osteogenic sarcoma in 3 cases, vascular endotheliosarcoma of the left iliac fossa in 1 case, neurofibroma of the left upper extremity in 1 case, lymphoma of double groin in 1 case.
  • Tumor located in neck in 33 cases including carotid body tumor in 32 cases and neurofibroma of the left upper extremity in 1 case.
  • RESULTS: Complete resection of tumor was in 72 cases, with a rate of 93.5%, palliative resection of tumor was in 5 cases with a rate of 6.5%.
  • Temporary shunt of carotid artery for neck tumor was used in 18 cases.
  • No death occurred for benign tumor.
  • CONCLUSION: The radical resection rate for tumor involving important vessel may be improved with the help of vascular technique.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Treatment Outcome. Vena Cava, Inferior / pathology. Vena Cava, Inferior / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18005586.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


61. Floyd HS, Farnsworth CL, Kock ND, Mizesko MC, Little JL, Dance ST, Everitt J, Tichelaar J, Whitsett JA, Miller MS: Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model. Carcinogenesis; 2005 Dec;26(12):2196-206
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model.
  • To determine the effects of expression of mutant Ki-ras on lung tumorigenesis, we developed a bitransgenic mouse model that expresses the human Ki-ras(G12C) allele in alveolar type II and/or Clara cells in a tetracycline-inducible, lung-specific manner.
  • Expression of Ki-ras(G12C) caused multiple, small lung tumors over a 12-month time period.
  • Although tumor multiplicity increased upon continued Ki-ras expression, most lung lesions were hyperplasias or well-differentiated adenomas.
  • This is in contrast to the more severe phenotypes observed in other transgenic mouse models in which different mutant Ki-ras alleles were expressed in the lung.
  • Withdrawal of doxycycline for 1 month resulted in almost a complete absence of proliferative pulmonary lesions, suggesting tumor regression in the absence of Ki-ras expression.
  • Mutant Ki-ras(G12C) expression was sufficient for initial lung tumor transformation, required for maintenance of tumor phenotype, and induced transformation of lung epithelial cells by the activation of multiple effector pathways.
  • These results describe a novel mouse lung tumor model demonstrating benign tumor development in the absence of tumor progression, which will provide a new tool for understanding the early stages of lung tumor pathogenesis.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - FVB-Tg(tetO/CMV-KRAS*G12C)9.1Msmi/J (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 1999 Nov;20(11):2159-65 [10545420.001]
  • [Cites] Trends Cell Biol. 2000 Apr;10(4):147-54 [10740269.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):11858-64 [10766812.001]
  • [Cites] Lancet. 2000 Feb 5;355(9202):479-85 [10841143.001]
  • [Cites] Br J Cancer. 2000 Aug;83(4):473-9 [10945494.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Sep;279(3):L452-9 [10956619.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):38973-80 [10978313.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6551-8 [11641780.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3249-62 [11751631.001]
  • [Cites] Transgenic Res. 2002 Feb;11(1):21-9 [11874100.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 May;26(5):558-64 [11970907.001]
  • [Cites] J Biol Chem. 2002 Jun 21;277(25):22743-9 [11927601.001]
  • [Cites] J Pathol. 2002 Jul;197(4):527-35 [12115868.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10482-7 [12145322.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):29510-8 [12039958.001]
  • [Cites] J Biol Chem. 2002 Aug 30;277(35):31808-17 [12082106.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):111-20 [12957286.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):40231-8 [12885771.001]
  • [Cites] J Biol Chem. 2004 Jan 9;279(2):1050-9 [14593117.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):9-20 [14712206.001]
  • [Cites] Development. 2004 Feb;131(4):953-64 [14757645.001]
  • [Cites] Oncogene. 2004 Feb 5;23(5):1166-76 [14647414.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2307-16 [15059877.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):375-87 [15093544.001]
  • [Cites] Dev Dyn. 2004 Sep;231(1):57-71 [15305287.001]
  • [Cites] N Engl J Med. 1987 Oct 8;317(15):929-35 [3041218.001]
  • [Cites] Cancer Res. 1988 Oct 15;48(20):5738-41 [3048648.001]
  • [Cites] Mol Carcinog. 1990;3(5):287-95 [2244961.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1085-9 [1996309.001]
  • [Cites] Cancer Res. 1991 Mar 15;51(6):1744-8 [1998965.001]
  • [Cites] J Natl Cancer Inst. 1991 Jul 17;83(14):1024-7 [2072410.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1353-62 [1679529.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18):4999-5002 [1654209.001]
  • [Cites] Am J Physiol. 1991 Oct;261(4 Pt 1):L349-56 [1928370.001]
  • [Cites] Cancer Res. 1992 May 15;52(10):2903-6 [1581907.001]
  • [Cites] J Biol Chem. 1992 Jul 25;267(21):14703-12 [1634515.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5342-52 [1394139.001]
  • [Cites] Dev Biol. 1993 Apr;156(2):426-43 [8462742.001]
  • [Cites] Cancer Res. 1993 Apr 15;53(8):1743-6 [8467490.001]
  • [Cites] Oncogene. 1993 Sep;8(9):2407-12 [8395679.001]
  • [Cites] J Biol Chem. 1995 Feb 10;270(6):2689-94 [7852338.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1444-7 [7882350.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Feb;12(2):110-6 [7535083.001]
  • [Cites] Carcinogenesis. 1996 Jul;17(7):1519-26 [8706258.001]
  • [Cites] Exp Lung Res. 1997 Jan-Feb;23(1):35-49 [9028798.001]
  • [Cites] Cell. 1997 Mar 7;88(5):593-602 [9054499.001]
  • [Cites] Oncogene. 1997 May 29;14(21):2595-607 [9191059.001]
  • [Cites] Carcinogenesis. 1997 Jun;18(6):1163-8 [9214598.001]
  • [Cites] Oncogene. 1997 Sep 4;15(10):1151-9 [9294608.001]
  • [Cites] Oncogene. 1997 Oct 9;15(15):1781-6 [9362444.001]
  • [Cites] Exp Lung Res. 1998 Jul-Aug;24(4):541-55 [9659582.001]
  • [Cites] Clin Chem Lab Med. 1998 May;36(5):255-69 [9676381.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):411-8 [9816185.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2281-90 [10327074.001]
  • [Cites] Cytokine. 1999 Apr;11(4):305-12 [10328870.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Dec 15;201(3):295-302 [15582647.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):48-55 [15608639.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):13809-16 [15668254.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3155-62 [15867207.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • (PMID = 16051643.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / T32 ES007331; United States / NCI NIH HHS / CA / R01 CA91909; United States / NCI NIH HHS / CA / R01 CA091909-02; United States / NCI NIH HHS / CA / P30 CA12197; United States / NCI NIH HHS / CA / R01 CA091909-02S1; United States / NCI NIH HHS / CA / R01 CA091909; United States / NIEHS NIH HHS / ES / T32-ES07331; United States / NCI NIH HHS / CA / R01 CA091909-04S1; United States / NCI NIH HHS / CA / R01 CA091909-04; United States / NCI NIH HHS / CA / R01 CA091909-03S1; United States / NCI NIH HHS / CA / P30 CA012197; United States / NCI NIH HHS / CA / R01 CA091909-01A1; United States / NCI NIH HHS / CA / R01 CA091909-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; EC 2.7.1.- / MAP-kinase-activated kinase 2; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / RPS6KA1 protein, human; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 90-kDa; EC 2.7.11.1 / Rps6ka1 protein, mouse; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.6.5.2 / ral GTP-Binding Proteins; N12000U13O / Doxycycline
  • [Other-IDs] NLM/ NIHMS6241; NLM/ PMC1351110
  •  go-up   go-down


62. Zheng JP, Shao GL, Chen YT, Fan SF, Yang JM: [Feasibility study on CT guided percutaneous incisional needle biopsy for deep pelvic masses by different puncture approaches]. Zhonghua Zhong Liu Za Zhi; 2009 Oct;31(10):786-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-four malignant lesions were confirmed by pathology, including 30 adenocarcinomas, 19 squamous cell carcinomas, 5 unclassified malignant tumors, 3 small cell carcinomas, 2 malignant giant cell tumors of bone, 2 hepatocellular carcinomas and 3 false negative lesions which were confirmed at the second PINBs as malignant tumors, respectively.
  • Benign neoplasms were confirmed in 8 cases, including fibrosis tissue in 6 lesions, bone tuberculosis in 1 and ovarian cyst in 1.
  • No hematoma, nerve damage, infection, and tumor transplantation in pelvic cavity developed after the PINB procedure.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colorectal Neoplasms / pathology. Colorectal Neoplasms / radiography. Diagnosis, Computer-Assisted / methods. Feasibility Studies. Female. Fibrosis / pathology. Fibrosis / radiography. Follow-Up Studies. Humans. Lung Neoplasms / pathology. Lung Neoplasms / radiography. Male. Middle Aged. Tomography, X-Ray Computed. Uterine Neoplasms / pathology. Uterine Neoplasms / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021836.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


63. Altamirano-Ley J, Estrada-Sánchez GR, Ochoa-Carrillo FJ: [Positron emission tomography and computed tomography (PET/CT) in lung cancer]. Cir Cir; 2007 Jul-Aug;75(4):303-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Positron emission tomography and computed tomography (PET/CT) in lung cancer].
  • [Transliterated title] Tomografía por emisión de positrones y tomografía computarizada (PET/CT) en carcinoma de pulmón.
  • BACKGROUND: Lung cancer is the most frequent cause of death due to neoplasm in Western populations, with >660,000 new diagnoses of lung cancer per year according to the World Health Organization.
  • METHODS: We undertook this study to emphasize the role of positron emission tomography to all health care professionals involved in lung cancer diagnosis.
  • One relatively common cause of false positives is the vocal cord and adjacent muscles contralateral and compensatory to the lung lesion that show an increased uptake of (18)FDG because of lesions in the laryngeal nerve by the tumor or secondary to surgery.
  • CONCLUSIONS: There is sufficient scientific evidence pointing to the usefulness of PET studies and its evolution to PET/CT, especially in patients with lung cancer.
  • This can resolve doubts by the oncologist and patient when there is a suspicious malignant lesion by the following: characterizing solitary pulmonary nodules (benign or malignant), localizing the optimal site for the biopsy, diagnosis of the primary tumor for initial staging, evaluation of mediastinal involvement and distant metastasis, evaluate and restage residual tumor, assessment of recurrence, monitoring response, prognostic prediction and radiotherapy planning.
  • [MeSH-major] Lung Neoplasms / diagnosis. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Diagnosis, Differential. Humans. Neoplasm Metastasis. Neoplasm Staging. Solitary Pulmonary Nodule / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053364.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Number-of-references] 50
  •  go-up   go-down


64. Sen S, Senturk E, Kuman NK, Pabuscu E, Kacar F: PEComa (clear cell "sugar" tumor) of the lung: a benign tumor that presented with thrombocytosis. Ann Thorac Surg; 2009 Dec;88(6):2013-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PEComa (clear cell "sugar" tumor) of the lung: a benign tumor that presented with thrombocytosis.
  • Perivascular epithelioid cell tumors of the lung are rare, benign neoplasms, usually presenting as a solitary pulmonary nodule on chest roentgenograms.
  • Most lesions are solitary and asymptomatic, and are located within the peripheral lung.
  • This is a case report of a 44-year-old woman who presented with thrombocytosis and solitary pulmonary nodule of the lung, which was removed by a thoracotomy.
  • [MeSH-major] Lung Neoplasms / diagnosis. Perivascular Epithelioid Cell Neoplasms / diagnosis. Thrombocytosis / complications
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Platelet Count. Pneumonectomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19932282.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


65. Fainstein Day P, Frohman L, Garcia Rivello H, Reubi JC, Sevlever G, Glerean M, Fernandez Gianotti T, Pietrani M, Rabadan A, Racioppi S, Bidlingmaier M: Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment. Pituitary; 2007;10(3):311-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment.
  • Although clinical improvement is common after treatment with somatostatin (SMS) analogs, the biochemical response and tumor size of the growth hormone-releasing hormone (GHRH)-producing tumor and its metastases are less predictable.
  • He had undergone lung surgery in 1987 for a "benign" carcinoid tumor.
  • Methods Measurement of circulating GHRH levels by fluorescence immunoassay levels and immunohistochemical study of the primary lung tumor and metastatic tissue with anti-GHRH and anti-somatostatin receptor type 2 (sst2A) antibodies.
  • Pathological study of liver and bone biopsy material and lung tissue removed 19 years earlier was consistent with an atypical carcinoid producing GHRH and exhibiting sst2A receptor expression.
  • No changes were observed in lung and liver metastases.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Bronchial Neoplasms / secondary. Bronchial Neoplasms / secretion. Carcinoid Tumor / secondary. Carcinoid Tumor / secretion. Growth Hormone-Releasing Hormone / secretion. Hormones, Ectopic / secretion. Human Growth Hormone / secretion. Octreotide / therapeutic use

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1988 Aug;67(2):395-9 [2899089.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3162-9 [10487681.001]
  • [Cites] Endocr Rev. 1988 Aug;9(3):357-73 [3145190.001]
  • [Cites] J Clin Invest. 1986 Oct;78(4):906-13 [3093533.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):246-54 [8532003.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1356-9; discussion 1360 [12015856.001]
  • [Cites] Endocr Rev. 1998 Dec;19(6):798-827 [9861546.001]
  • [Cites] Endokrynol Pol. 2006 Jan-Feb;57(1):32-6 [16575760.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2104-9 [15671091.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jul;57(1):131-4 [12100081.001]
  • [Cites] J Thorac Cardiovasc Surg. 1985 Jun;89(6):819-25 [2582209.001]
  • [Cites] Endocrinol Metab Clin North Am. 1991 Sep;20(3):507-18 [1935918.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Nov;90(11):6156-61 [16091489.001]
  • [Cites] Clin Endocrinol (Oxf). 1991 Jun;34(6):463-7 [1653654.001]
  • [Cites] Science. 1998 Jan 23;279(5350):563-6 [9438850.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):221-6 [2891432.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S89-94 [11762359.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1642-51 [16327437.001]
  • [Cites] Neurochirurgia (Stuttg). 1992 Sep;35(5):160-2 [1436366.001]
  • [Cites] J Clin Invest. 1980 Jan;65(1):43-54 [6243140.001]
  • [Cites] Endocrinology. 1989 Aug;125(2):801-9 [2502376.001]
  • [Cites] Cancer Res. 1998 Jun 1;58(11):2375-8 [9622077.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2605-13 [15495181.001]
  • [Cites] Eur J Nucl Med. 1998 Jul;25(7):675-86 [9662588.001]
  • [Cites] J Laryngol Otol. 2005 May;119(5):405-8 [15949110.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3104-9 [9745411.001]
  • [Cites] J Physiol Paris. 2000 May-Aug;94(3-4):205-10 [11087998.001]
  • [Cites] Am J Clin Pathol. 1986 Jan;85(1):13-20 [3000164.001]
  • [Cites] Ann Thorac Surg. 1996 Sep;62(3):798-809; discussion 809-10 [8784011.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):955-62 [16954443.001]
  • [Cites] Front Neuroendocrinol. 1999 Jul;20(3):157-98 [10433861.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):575-95 [1521513.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Aug;61(2):224-31 [15272918.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Feb;68(2):499-504 [2493033.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Jul;55(1):135-40 [11453963.001]
  • [Cites] Eur J Endocrinol. 1995 Sep;133(3):320-4 [7581949.001]
  • (PMID = 17373589.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Blood Glucose; 0 / Hormones, Ectopic; 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; 12629-01-5 / Human Growth Hormone; 9034-39-3 / Growth Hormone-Releasing Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


66. Chen G, Liu XY, Wang Z, Liu FY: Vascular endothelial growth factor C: the predicator of early recurrence in patients with N2 non-small-cell lung cancer. Eur J Cardiothorac Surg; 2010 Mar;37(3):546-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor C: the predicator of early recurrence in patients with N2 non-small-cell lung cancer.
  • OBJECTIVE: Mediastinal lymph node metastasis (N2) is a key prognostic factor for lung carcinoma.
  • This study was undertaken to investigate the relationship between vascular endothelial growth factor C (VEGF-C) expression and postoperative early recurrence in patients with N2 non-small-cell lung cancer.
  • METHODS: Cancer tissue samples from 92 patients with pN2 non-small-cell lung cancer and benign lung disease tissues samples from 30 patients were examined by reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry assays to detect VEGF-C expression.
  • All patients with N2 disease were evaluated within 1 year after surgery to detect early tumour recurrence.
  • Cox regression analysis was performed to determine the risk factors of postoperative early recurrence of N2 lung cancer.
  • RESULTS: VEGF-C mRNA expression was observed in 64 (70%) pN2 lung cancer tissues, but was not found in benign lung disease tissues.
  • The main pattern was distant recurrence, and the most frequent sites were the brain and lung.
  • Cox regression analysis revealed that positive VEGF-C expression in tumours (hazard ratio (HR)=2.523, P=0.037) was an independent risk factor of postoperative early recurrence of N2 lung cancer.
  • CONCLUSIONS: VEGF-C expression was high in N2 lung cancer, with significant correlation to postoperative early recurrence.
  • About one-half of the patients with N2 non-small-cell lung cancer would develop recurrence disease within 1 year after surgery, frequently with mediastinal nodes, brain or lung metastases.
  • VEGF-C might be a predictor of postoperative early recurrence in patients with N2 non-small-cell lung cancer.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Vascular Endothelial Growth Factor C / biosynthesis
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / secondary. Chemotherapy, Adjuvant. Epidemiologic Methods. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Radiotherapy, Adjuvant. Reverse Transcriptase Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • (PMID = 19758816.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / VEGFC protein, human; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


67. Banerjee S, Byrd JN, Gianino SM, Harpstrite SE, Rodriguez FJ, Tuskan RG, Reilly KM, Piwnica-Worms DR, Gutmann DH: The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. Cancer Res; 2010 Feb 15;70(4):1356-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo.
  • Neurofibromatosis type 1 (NF1) is a common cancer predisposition syndrome in which affected individuals develop benign and malignant nerve tumors.
  • The NF1 gene product neurofibromin negatively regulates Ras and mammalian target of rapamycin (mTOR) signaling, prompting clinical trials to evaluate the ability of Ras and mTOR pathway inhibitors to arrest NF1-associated tumor growth.
  • To discover other downstream targets of neurofibromin, we performed an unbiased cell-based high-throughput chemical library screen using NF1-deficient malignant peripheral nerve sheath tumor (MPNST) cells.
  • [MeSH-minor] Animals. Animals, Newborn. Cells, Cultured. Chromones / pharmacology. Enzyme Inhibitors / pharmacology. Gene Expression Regulation / drug effects. Genes, Tumor Suppressor / physiology. Humans. Intracellular Signaling Peptides and Proteins / metabolism. Male. Mice. Mice, Nude. Mice, Transgenic. Morpholines / pharmacology. Protein-Serine-Threonine Kinases / metabolism. Signal Transduction / drug effects. Signal Transduction / genetics. TOR Serine-Threonine Kinases. Triterpenes / pharmacology. Xenograft Model Antitumor Assays


68. Sheng SL, Huang G, Yu B, Qin WX: Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem; 2009 Sep;55(9):1656-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer.
  • Clinical significance of serum DKK1 in lung cancer remains to be determined.
  • By use of this method, we investigated the serum concentrations of DKK1 in 592 patients with malignancies, 72 patients with benign lung disease, and 120 healthy controls.
  • RESULTS: Serum DKK1 concentrations were significantly higher in patients with lung cancer than in patients with other malignant tumors or benign lung diseases and healthy controls.
  • Application of both DKK1 and cytokeratin 19 fragment increased sensitivity, correctly identifying 89.6% of the non-small cell lung cancer patients as positive.
  • The use of both DKK1 and neuron-specific enolase increased sensitivity to detect small cell lung cancer to 86.2%.
  • DKK1 concentrations increased with stage, tumor class, and presence of lymph node and distant metastases, regardless of histology and patient age and sex.
  • CONCLUSIONS: DKK1 was preferentially expressed in lung cancer.
  • Increasing concentrations of DKK1were significantly associated with tumor progression and decreased survival in patients with lung cancer. .
  • [MeSH-major] Biomarkers, Tumor / blood. Fluoroimmunoassay / methods. Intercellular Signaling Peptides and Proteins / blood. Lung Neoplasms / blood
  • [MeSH-minor] Aged. Calibration. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19628661.001).
  • [ISSN] 1530-8561
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DKK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


69. Belizon A, Balik E, Feingold DL, Bessler M, Arnell TD, Forde KA, Horst PK, Jain S, Cekic V, Kirman I, Whelan RL: Major abdominal surgery increases plasma levels of vascular endothelial growth factor: open more so than minimally invasive methods. Ann Surg; 2006 Nov;244(5):792-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Vascular endothelial growth factor (VEGF) is a potent inducer of angiogenesis that is necessary for wound healing and also promotes tumor growth.
  • It is anticipated that plasma levels would increase after major surgery and that such elevations may facilitate tumor growth.
  • METHODS: Colorectal resection for cancer (n = 139) or benign pathology (n = 48) and gastric bypass for morbid obesity (n = 40) were assessed.
  • RESULTS: The mean preoperative VEGF level of the cancer patients was significantly higher than baseline level of benign colon patients.
  • CONCLUSION: As a group colon cancer patients prior to surgery have significantly higher mean VEGF levels than patients without tumors.

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Weight Loss Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):657-62 [11078612.001]
  • [Cites] Br J Surg. 2001 Aug;88(8):1105-9 [11488797.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):417-23 [11875709.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):36-9 [11961601.001]
  • [Cites] Surgery. 2002 May;131(5):548-55 [12019409.001]
  • [Cites] Transfusion. 1999 Oct;39(10):1078-83 [10532601.001]
  • [Cites] Jpn J Cancer Res. 1999 Aug;90(8):874-9 [10543260.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):333-8 [10671682.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3147-52 [10955796.001]
  • [Cites] World J Surg. 2000 Oct;24(10):1264-70 [11071473.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):37-42 [12131083.001]
  • [Cites] Surg Endosc. 2002 Aug;16(8):1162-9 [11984655.001]
  • [Cites] Surgery. 2002 Aug;132(2):186-92 [12219010.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2002 Nov;283(5):L1133-42 [12376368.001]
  • [Cites] Gastric Cancer. 2002;5(3):137-41 [12378339.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(3-4):271-4 [12807238.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Oct;27(10):1187-95 [14513066.001]
  • [Cites] J Immunol. 2003 Oct 15;171(8):4340-51 [14530359.001]
  • [Cites] J Surg Res. 2003 Nov;115(1):113-20 [14572781.001]
  • [Cites] Cytokine. 2004 Jan 21;25(2):68-72 [14693162.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):270-8 [14716760.001]
  • [Cites] Surgery. 1986 Aug;100(2):273-7 [3738755.001]
  • [Cites] Cancer Detect Prev. 1988;12(1-6):421-9 [3263198.001]
  • [Cites] Nihon Geka Gakkai Zasshi. 1989 Aug;90(8):1245-50 [2811843.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Arch Surg. 1995 Jun;130(6):649-53 [7763175.001]
  • [Cites] Nat Biotechnol. 1997 Jun;15(6):510 [9181567.001]
  • [Cites] Br J Cancer. 1998 Mar;77(6):956-64 [9528841.001]
  • [Cites] Dis Colon Rectum. 1998 May;41(5):564-9 [9593237.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1279-85 [9607588.001]
  • [Cites] Clin Sci (Lond). 1998 Apr;94(4):395-404 [9640345.001]
  • [Cites] Surg Endosc. 1998 Aug;12(8):1035-8 [9685537.001]
  • [Cites] Surgery. 1998 Sep;124(3):516-25 [9736904.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1419-24 [9769380.001]
  • [Cites] Br J Surg. 1998 Oct;85(10):1439-42 [9782033.001]
  • [Cites] Chest. 1998 Dec;114(6):1668-75 [9872204.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] Lancet. 1999 Jan 30;353(9150):345-50 [9950438.001]
  • [Cites] Surg Endosc. 1999 Mar;13(3):233-5 [10064753.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2041-5 [10070308.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):487-91 [10100697.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] Dis Colon Rectum. 1999 Apr;42(4):477-81 [10215047.001]
  • [Cites] Ann Oncol. 1999 Aug;10(8):965-71 [10509160.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4804-7 [10519388.001]
  • [Cites] Surg Endosc. 2005 Jan;19(1):55-9 [15531967.001]
  • [Cites] Int J Obes (Lond). 2005 Nov;29(11):1308-14 [15953938.001]
  • [Cites] Surg Endosc. 2006 Mar;20(3):482-6 [16432654.001]
  • [CommentIn] Ann Surg. 2007 Jul;246(1):160-1; author reply 161 [17592305.001]
  • (PMID = 17060773.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC1856599
  •  go-up   go-down


70. Takeuchi A, Yamamoto Y, Tsuneyama K, Cheng C, Yonekura H, Watanabe T, Shimizu K, Tomita K, Yamamoto H, Tsuchiya H: Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma. Cancer; 2007 Jun 15;109(12):2532-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Chondrosarcoma, the second most frequent primary malignant bone tumor, is classified into 3 grades according to histologic criteria of malignancy.
  • However, a low-grade lesion can be difficult to distinguish from a benign enchondroma, whereas some histologically low-grade lesions may carry a poor prognosis.
  • Associations of these molecules with histology and clinical behavior of tumors were analyzed.
  • High expression of esRAGE in grade 1 chondrosarcoma was associated with subsequent recurrence (P = .0013), lung metastasis (P = .0071), and poor survival (P < .001).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Bone Neoplasms / metabolism. Chondroma / metabolism. Chondrosarcoma / metabolism. Receptors, Immunologic / metabolism

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 American Cancer Society.
  • (PMID = 17497647.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Advanced Glycosylation End Product-Specific Receptor; 0 / Biomarkers, Tumor; 0 / Glycosylation End Products, Advanced; 0 / HMGB1 Protein; 0 / Receptors, Immunologic
  •  go-up   go-down


71. Henske EP: Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond. Pediatr Nephrol; 2005 Jul;20(7):854-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The renal manifestations of tuberous sclerosis complex (TSC) are remarkably diverse, including polycystic kidney disease, oncocytomas, renal cell carcinomas, and both benign and malignant angiomyolipomas.
  • Benign angiomyolipomas, which can cause spontaneous life-threatening hemorrhage, are by far the most prevalent and the greatest source of morbidity.
  • [MeSH-minor] Humans. Mutation. Repressor Proteins / genetics. Repressor Proteins / metabolism. Signal Transduction. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2000 May;2(5):281-7 [10806479.001]
  • [Cites] Am J Hum Genet. 2001 Jan;68(1):64-80 [11112665.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):147-58 [12957289.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1305-15 [8269512.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):457-68 [12547704.001]
  • [Cites] Am J Hum Genet. 1999 May;64(5):1305-15 [10205261.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6356-65 [12214276.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Apr;286(4):L694-700 [12922981.001]
  • [Cites] Am J Hum Genet. 2001 Sep;69(3):493-503 [11468687.001]
  • [Cites] Oncogene. 2004 Apr 19;23(18):3151-71 [15094765.001]
  • [Cites] Oncogene. 2002 Dec 5;21(55):8470-6 [12466966.001]
  • [Cites] Hum Mol Genet. 1998 Jun;7(6):1053-7 [9580671.001]
  • [Cites] J Urol. 1998 Jul;160(1):141-5 [9628635.001]
  • [Cites] Pediatr Radiol. 2002 Sep;32(9):677-80 [12195309.001]
  • [Cites] Lancet. 2003 Apr 19;361(9366):1348-9 [12711473.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):180-7 [9500218.001]
  • [Cites] Cell. 2003 Nov 26;115(5):577-90 [14651849.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):491-500 [12547707.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2208-16 [9827727.001]
  • [Cites] Cancer Res. 1998 Nov 1;58(21):4766-70 [9809973.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):663-72 [9630173.001]
  • [Cites] Mod Pathol. 2002 Mar;15(3):205-10 [11904337.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2163-72 [14634372.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):29930-7 [15150271.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2675-80 [12750296.001]
  • [Cites] Mayo Clin Proc. 1991 Aug;66(8):792-6 [1861550.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51372-9 [14551205.001]
  • [Cites] Am J Pathol. 1996 Oct;149(4):1201-8 [8863669.001]
  • [Cites] Mol Cell. 2001 Apr;7(4):823-32 [11336705.001]
  • [Cites] J Clin Invest. 1997 Jan 15;99(2):194-9 [9005987.001]
  • [Cites] Am J Hum Genet. 1996 Aug;59(2):400-6 [8755927.001]
  • [Cites] Urology. 1991 Apr;37(4):340-3 [2014599.001]
  • [Cites] Eur J Radiol. 1998 May;27(2):131-8 [9639138.001]
  • [Cites] Nat Genet. 1994 Dec;8(4):328-32 [7894481.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):193-6 [8162074.001]
  • [Cites] Hum Mol Genet. 1994 Oct;3(10):1829-32 [7849708.001]
  • [Cites] Kidney Int. 2004 Sep;66(3):924-34 [15327383.001]
  • [Cites] J Pediatr Surg. 1996 May;31(5):729-30 [8861495.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):889-94 [10843294.001]
  • [Cites] Hum Mol Genet. 1994 Oct;3(10):1833-4 [7849709.001]
  • [Cites] Science. 1997 Aug 8;277(5327):805-8 [9242607.001]
  • (PMID = 15856327.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK 51052
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Repressor Proteins; 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein
  • [Number-of-references] 43
  •  go-up   go-down


72. Zhang XZ, Xiao ZF, Li C, Xiao ZQ, Yang F, Li DJ, Li MY, Li F, Chen ZC: Triosephosphate isomerase and peroxiredoxin 6, two novel serum markers for human lung squamous cell carcinoma. Cancer Sci; 2009 Dec;100(12):2396-401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triosephosphate isomerase and peroxiredoxin 6, two novel serum markers for human lung squamous cell carcinoma.
  • There is currently substantial interest in the identification of human tumor antigens for the diagnosis and immunotherapy of cancer.
  • In our previous study, secretion character and up-regulation of triosephosphate isomerase were observed in lung squamous cell carcinoma, and autoantibodies against triosephosphate isomerase and peroxiredoxin 6 were detected in the sera from over 25% of patients, but in none of the healthy controls.
  • Up-regulated triosephosphate isomerase and peroxiredoxin 6 were further validated by enzyme-linked immunosorbent assay in an additional 61 lung squamous cell carcinoma patients, 23 lung adenocarcinoma patients, 56 other types of carcinoma patients, 12 benign lung disease patients, and 59 healthy controls.
  • We found that both triosephosphate isomerase and peroxiredoxin 6 were specifically elevated in lung squamous cell carcinoma sera compared with other groups, with the exception of peroxiredoxin 6 in lung adenocarcinoma patients.
  • At the cut-off point 0.221 (optical density value) on the receiver operating characteristic curve, triosephosphate isomerase could comparatively discriminate lung squamous cell carcinoma from healthy controls with a sensitivity of 65.6%, specificity 84.7%, and total accuracy 75%.
  • With both triosephosphate isomerase and peroxiredoxin 6, discriminant analysis results showed that 68.9% of the lung squamous cell carcinoma and 83.1% of healthy controls were correctly classified.
  • We concluded that triosephosphate isomerase and peroxiredoxin 6 could be markers for lung squamous cell carcinoma.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Squamous Cell / blood. Lung Neoplasms / blood. Peroxiredoxin VI / blood. Triose-Phosphate Isomerase / blood

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19737146.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.11.1.15 / Peroxiredoxin VI; EC 5.3.1.1 / Triose-Phosphate Isomerase
  •  go-up   go-down


73. Wang WB, Cui YG, Yao SY: [Message RNA expression of LUNX, CK19 and CEA genes in NSCLC with micrometastasis in lymph nodes]. Zhonghua Zhong Liu Za Zhi; 2008 Feb;30(2):121-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the correlation of mRNA expression level of three cancer-associated genes-LUNX mRNA, CK19 mRNA and CEA mRNA with metastasis in lymph nodes and histopathological staging in non-small cell lung cancer (NSCLC).
  • METHODS: Fifty-six tumor tissue samples and 103 regional lymph node samples were obtained from 56 patients with NSCLC, and another 35 lymph node samples as control from 15 patients with benign pulmonary diseases.
  • RESULTS: mRNA expression of LUNX, CK19 and CEA genes in the regional lymph nodes of NSCLC was significantly higher than that in those of benign lung diseases (P < 0.05).
  • No significant correlation was found between positive mRNA expression of LUNX mRNA and CK19 mRNA in the lymph nodes and histopathologic type of lung cancer (P > 0.05).
  • CONCLUSION: LUNX mRNA and CK19 mRNA may serve as a molecular marker for detection of lymph node micrometastasis in patient with non-small cell lung cancer, but LUNX mRNA is superior to CK19 mRNA in both sensitivity and specificity.
  • [MeSH-major] Carcinoembryonic Antigen / metabolism. Glycoproteins / metabolism. Keratin-19 / metabolism. Lung Neoplasms / metabolism. Lymph Nodes / metabolism. Phosphoproteins / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18646695.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BPIFA1 protein, human; 0 / Carcinoembryonic Antigen; 0 / Glycoproteins; 0 / Keratin-19; 0 / Phosphoproteins; 0 / RNA, Messenger
  •  go-up   go-down


74. Ohba Y, Nomori H, Mori T, Ikeda K, Shibata H, Kobayashi H, Shiraishi S, Katahira K: Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F 18 in imaging non-small cell lung cancer? J Thorac Cardiovasc Surg; 2009 Aug;138(2):439-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F 18 in imaging non-small cell lung cancer?
  • OBJECTIVE: This retrospective analysis examined whether diffusion-weighted magnetic resonance imaging might be as useful as positron emission tomography with fludeoxyglucose F 18 for (1) discriminating between non-small cell lung cancer and benign pulmonary nodules and (2) predicting aggressiveness of non-small cell lung cancer.
  • METHODS: Diffusion-weighted magnetic resonance imaging and positron emission tomography were performed before surgery in 110 patients with 124 pulmonary nodules smaller than 3 cm, including 96 non-small cell lung cancers and 28 benign nodules.
  • The criterion standard was the result of histologic diagnosis or follow-up examination.
  • Sensitivity and specificity for differentiating between cancers and benign nodules were compared between diffusion-weighted imaging and positron emission tomography.
  • Apparent diffusion coefficient in diffusion-weighted imaging and fludeoxyglucose F 18 uptake in positron emission tomography were examined with respect to pathologic tumor stage; lymphatic, vascular and pleural involvements; and histologic differentiation.
  • RESULTS: There were no significant differences between diffusion-weighted magnetic resonance imaging and positron emission tomography in sensitivity or specificity for non-small cell lung cancer.
  • Whereas positron emission tomography showed significant differences in fludeoxyglucose F 18 uptake between pathologic stages IA versus IB or more advanced stages; between tumors with and without lymphatic, vascular, or pleural involvement; and between well-differentiated and moderately or poorly differentiated adenocarcinomas (P <.01-0.001), no significant differences in apparent diffusion coefficient values in were observed.
  • CONCLUSION: Diffusion-weighted magnetic resonance imaging is equivalent to positron emission tomography in distinguishing non-small cell lung cancer from benign pulmonary nodules but is not as useful for predicting aggressiveness of non-small cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Diffusion Magnetic Resonance Imaging. Fluorodeoxyglucose F18. Lung Neoplasms / diagnosis. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19619793.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


75. Heffner JE, Klein JS: Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc; 2008 Feb;83(2):235-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in the diagnosis and management of malignant pleural effusions.
  • Median survival after diagnosis of an MPE is 4 months.
  • Common cancer types causing MPEs include lymphomas, mesotheliomas, and carcinomas of the breast, lung, gastrointestinal tract, and ovaries.
  • However, almost all tumor types have been reported to cause MPEs.
  • New imaging modalities assist the evaluation of patients with a suspected MPE; however, positive cytologic or tissue confirmation of malignant cells is necessary to establish a diagnosis.
  • Even in the presence of known malignancy, up to 50% of pleural effusions are benign, underscoring the importance of a firm diagnosis to guide therapy.
  • This review summarizes the pathogenesis, diagnosis, and management of MPE.
  • [MeSH-major] Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / therapy

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Mayo Clin Proc. 2009 Sep;84(9):847
  • (PMID = 18241636.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 224
  •  go-up   go-down


76. Yamamoto Y, Nishiyama Y, Ishikawa S, Gotoh M, Bandoh S, Kanaji N, Asakura M, Ohkawa M: 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose. J Comput Assist Tomogr; 2008 May-Jun;32(3):432-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose.
  • OBJECTIVE: The purpose of this study was to evaluate the accuracy of 3'-deoxy-3'-F-fluorothymidine (FLT) positron emission tomography (PET) for detection of lung tumor in comparison with 2-deoxy-2-F-fluoro-D-glucose (FDG) PET.
  • METHODS: Fifty-four patients with newly diagnosed pulmonary nodules on chest computed tomographic (CT) scan suggestive of a malignant tumor were examined with both FLT and FDG PET.
  • The intensity of uptake in lung tumors was scored.
  • RESULTS: Thirty-six patients were found to have lung cancer; and 18, benign lesions.
  • Using visual analysis, the sensitivity of FLT PET for detection of lung cancer was 83%; the specificity, 83%; and the accuracy, 83%.
  • The uptake of FLT in lung cancer was significantly lower than that of FDG.
  • CONCLUSIONS: These preliminary results indicate that FLT PET may be specific for malignant tumors although uptake of FLT in lung cancer was significantly lower than that of FDG.
  • [MeSH-major] Dideoxynucleosides. Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18520552.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dideoxynucleosides; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


77. Peng HQ, Greenwald BD, Tavora FR, Kling E, Darwin P, Rodgers WH, Berry A: Evaluation of performance of EUS-FNA in preoperative lymph node staging of cancers of esophagus, lung, and pancreas. Diagn Cytopathol; 2008 May;36(5):290-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of performance of EUS-FNA in preoperative lymph node staging of cancers of esophagus, lung, and pancreas.
  • We reviewed the cytologic and histologic diagnoses and EUS report of 77 consecutive patients who had undergone EUS-FNA preoperative staging for esophageal, lung, and pancreatic cancers at our institution.
  • We compared cytologically malignant and benign lymph node groups with eight EUS parameters including the total number of lymph nodes found by EUS, the shape, margin, long axis, short axis, echogenicity, location of the lymph node, and EUS tumor staging.
  • Lymph nodes found in an abdominal location in esophageal and lung cancer are likely malignant.
  • [MeSH-minor] Biopsy, Fine-Needle / methods. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Humans. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Lymphatic Metastasis / pathology. Neoplasm Staging. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18418852.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Kawamura S, Nakamura T, Oya T, Ishizawa S, Sakai Y, Tanaka T, Saito S, Fukuoka J: Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy. Pathol Int; 2007 Apr;57(4):213-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy.
  • Solitary fibrous tumor (SFT) is a rare spindle cell neoplasm that is benign in most cases.
  • Along with massive invasion to adjacent organs and multiple lung metastases detected on radiography, biopsy from the tumor through the vaginal wall showed malignant looking spindle-cell neoplasm with increased cellularity, areas of necrosis, and high mitotic activity (5/10 high-power fields).
  • Immunohistochemically, the tumor cells were diffusely and strongly positive for CD34, CD99, and bcl-2.
  • Based on pathological features and clinical presentation, diagnosis of malignant SFT was made.
  • Initial chemotherapies failed to control the tumor.
  • [MeSH-minor] Aged. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Neoplasm Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17316417.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


79. Afify AM, Stern R, Michael CW: Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol; 2005 Mar;32(3):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Archival paraffin-embedded cell blocks of serous fluids from 28 cases of reactive mesothelial cells, 14 cases of MM, 20 cases of metastatic ovarian carcinomas, 17 cases of metastatic breast carcinomas, 12 cases of metastatic lung ACA, and 12 cases of metastatic gastrointestinal ACA were stained with HA using a biotinylated HABP and CD44S.
  • All MMs and 93% (26/28) of the benign mesothelial cells were positive for intracytoplasmic HA vs. none of ACAs.
  • CD44S was expressed in 100% (28/28) of mesothelial hyperplesia, 86% (12/14) of MMs, 70% (14/20) of ovarian carcinomas, 29% (5/17) of breast carcinomas, 25% (3/12) of gastrointestinal ACAs, and 8% (1/12) of lung ACAs.
  • CD44 may prove useful in conjunction with other stains in the differential diagnosis of mesothelioma and ADA.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, CD44 / metabolism. Ascitic Fluid / metabolism. Hyaluronic Acid / metabolism. Mesothelioma / diagnosis. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neoplasm Metastasis. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690337.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44S antigen; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


80. Kawano Y, Tamura A, Goto Y, Shinozaki K, Zaizen H, Kadota J: Incidental detection of cancers and other non-cardiac abnormalities on coronary multislice computed tomography. Am J Cardiol; 2007 Jun 1;99(11):1608-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancers were found in 7 patients (1.13%) on the multislice computed tomographic images, including 4 lung cancers (0.65%), 2 thyroid cancers (0.32%), and 1 hepatic cancer (0.16%).
  • In addition, nonmalignant abnormalities (nodules, tumors, or lymphadenopathies) were also found in 142 patients (23.01%), consisting of 58 postinflammatory lung nodules (9.40%), 49 hepatic cysts or hemangiomas (7.94%), 18 benign thyroid tumors (2.92%), 12 mediastinal lymphadenopathies (1.94%), 4 benign mammary gland tumors (0.65%), and 1 esophageal submucosal tumor (0.16%).


81. Meirelles GS, Ravizzini G, Moreira AL, Akhurst T: Primary pulmonary meningioma manifesting as a solitary pulmonary nodule with a false-positive PET scan. J Thorac Imaging; 2006 Aug;21(3):225-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These lesions are usually benign, grow slowly, and have an excellent prognosis.
  • However, they can mimic any other pulmonary tumor, as the most common presentation is as a solitary pulmonary nodule.
  • We report a case of a primary pulmonary meningioma manifesting as a solitary lung nodule with a very high metabolic activity on the positron emission tomography, mimicking a primary lung cancer.
  • [MeSH-major] False Positive Reactions. Lung Neoplasms / radionuclide imaging. Meningioma / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16915069.001).
  • [ISSN] 0883-5993
  • [Journal-full-title] Journal of thoracic imaging
  • [ISO-abbreviation] J Thorac Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Revel MP, Merlin A, Peyrard S, Triki R, Couchon S, Chatellier G, Frija G: Software volumetric evaluation of doubling times for differentiating benign versus malignant pulmonary nodules. AJR Am J Roentgenol; 2006 Jul;187(1):135-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Software volumetric evaluation of doubling times for differentiating benign versus malignant pulmonary nodules.
  • OBJECTIVE: The purpose of our study was to evaluate the reliability of software-calculated doubling times for discerning malignant versus benign nodules.
  • MATERIALS AND METHODS: CT lung analysis volumetric software was used to retrospectively calculate the doubling times of 63 solid noncalcified nodules by comparing nodule volumes on baseline and follow-up CT scans obtained a median of 3.7 months apart.
  • A final diagnosis based on validated criteria was available for all 63 nodules.
  • Taking 500 days as the upper value for malignancies, we evaluated whether the software-calculated doubling times could be used to distinguish malignant from benign solid nodules.
  • We also examined whether the relative volume variation of benign nodules correlated with initial nodule size, interscan interval, or differences in contrast administration or exposure parameters between baseline and follow-up CT.
  • RESULTS: There were 52 benign and 11 malignant nodules.
  • Benign nodules had a median doubling time of 947 days and a mean relative volume variation of -4.4% (range, -50% to 38%).
  • No correlation was found between the relative volume variation of benign nodules and their initial size, the interscan interval, or differences in contrast administration or exposure parameters between the two CT examinations.
  • CONCLUSION: Software-calculated pulmonary nodule doubling times of more than 500 days have a 98% negative predictive value for the diagnosis of solid malignant pulmonary nodules.
  • [MeSH-major] Image Processing, Computer-Assisted. Lung / radiography. Lung Diseases / radiography. Solitary Pulmonary Nodule / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Imaging, Three-Dimensional. Lung Neoplasms. Male. Middle Aged. Software. Tumor Burden

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16794167.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Adachi Y, Horie Y, Kitamura Y, Nakamura H, Taniguchi Y, Miwa K, Fujioka S, Nishimura M, Hayashi K: CD1a expression in PEComas. Pathol Int; 2008 Mar;58(3):169-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • According to the World Health Organization classification, neoplasms with perivascular epithelioid cell differentiation (PEComas) are mesenchymal tumors composed of histologically and immunohistochemically distinctive PEC.
  • Recently the authors reported that benign clear cell sugar tumor of the lung, one of the PEComas, expressed CD1a.
  • Nineteen PEComas were obtained, which included angiomyolipoma of the kidney or liver, lymphangiomyomatosis of the uterus or lung and clear cell sugar tumor of the lung.
  • Eighteen tumors had alpha-SMA and HMB-45 expression and 16 had melan A expression.
  • In contrast, all 19 tumors had CD1a expression.
  • [MeSH-major] Antigens, CD1 / metabolism. Biomarkers, Tumor / metabolism. Epithelioid Cells / metabolism. Neoplasms, Connective and Soft Tissue / metabolism

  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251780.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD1; 0 / Biomarkers, Tumor; 0 / CD1a antigen
  •  go-up   go-down


84. Lu GH, Zhong XJ, Ding W, Zhou JY: [Expression of glucose transporter in non-small cell lung carcinoma and its clinical significance]. Zhejiang Da Xue Xue Bao Yi Xue Ban; 2008 Mar;37(2):176-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of glucose transporter in non-small cell lung carcinoma and its clinical significance].
  • OBJECTIVE: To investigate the expression of glucose transporter (Glut)1, Glut3, and hypoxia inducible factor (HIF)-1 alpha in human non-small cell lung carcinoma (NSCLC), and its clinical significance.
  • METHODS: Specimens of cancer tissues and paracancerous lung tissues from 34 cases of NSCLC and 17 specimens of benign lung lesions were collected.
  • RESULT: The relative mRNA expressions of Glut1 and HIF-1 alpha were 0.689 +/-0.245, 0.693 +/-0.248 in cancer tissues; and 0.338 +/-0.157, 0.351 +/-0.184 in paracancerous lung tissues (P <0.001); while those of Glut3 were 0.506 +/-0.246 in cancer tissues and 0.482 +/-0.238 in paracancerous tissues (P >0.05).
  • The relative protein expressions of Glut1 and HIF-1 alpha were 0.582 +/-0.247, 0.525 +/-0.246 in cancer tissues and 0.288 +/-0.151, 0.261 +/-0.135 in paracancerous lung tissues (P<0.001), but the protein expressions of Glut3 were 0.551 +/-0.251 and 0.436 +/-0.224 respectively (P>0.05).
  • CONCLUSION: Glut1 and HIF-1 alpha are highly expressed in NSCLC, and their expressions are associated with tumor differentiation and clinical stage.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Glucose Transporter Type 1 / metabolism. Glucose Transporter Type 3 / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Lung Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18422279.001).
  • [ISSN] 1008-9292
  • [Journal-full-title] Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  • [ISO-abbreviation] Zhejiang Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Glucose Transporter Type 3; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / SLC2A1 protein, human; 0 / SLC2A3 protein, human
  •  go-up   go-down


85. Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM: Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol; 2007 Mar;20(3):375-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberrant expression of human leukocyte antigen G (HLA-G) has been proposed to be involved in tumor escape mechanisms.
  • It has been also proposed that detection of HLA-G might service as a potential biomarker for diagnosis or prediction of the clinical outcomes in ovarian and breast cancers, carcinoma of the lung and endometrial cancer.
  • In this prospectively study, HLA-G protein expression was observed in 64.6% (130/201) of the primary site colorectal carcinomas, but not in the normal colorectal tissues or benign adenomas.
  • HLA-G expression in the tumors was significantly correlated with the depth of invasion, histological grade, host immune response, lymph nodal metastasis and clinical stages of the disease (P=0.001, 0.0001, 0.002, 0.001 and 0.031, respectively).
  • Patients with HLA-G positive tumors had a significantly shorter survival time than those patients with tumors that were HLA-G negative (P=0.0001).
  • [MeSH-major] Biomarkers, Tumor / analysis. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. HLA Antigens / biosynthesis. Histocompatibility Antigens Class I / biosynthesis
  • [MeSH-minor] Female. HLA-G Antigens. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277760.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


86. Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, Niki T, Shibahara J, Mori M, Makuuchi M, Hippo Y, Kodama T, Iwanari H, Aburatani H, Fukayama M: The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol; 2005 Dec;18(12):1591-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Then, we evaluated the feasibility of GPC3-immunohistochemistry in the pathological diagnosis of benign and malignant hepatocellular lesions by applying these monoclonal antibodies to formalin-fixed and paraffin-embedded specimens.
  • GPC3 immunoreactivity was detected in only one of 23 metastatic lesions of colorectal carcinoma, and its expression was entirely absent in the liver cell adenoma (0/7), carcinoid tumor (0/1), and cholangiocellular carcinoma (0/16).
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Hepatocellular / diagnosis. Heparan Sulfate Proteoglycans / metabolism. Liver Neoplasms / diagnosis
  • [MeSH-minor] Antibodies, Monoclonal / biosynthesis. Antibodies, Monoclonal / immunology. Cell Line, Tumor. Glypicans. Hepatoblastoma / metabolism. Hepatoblastoma / pathology. Hepatocytes / metabolism. Hepatocytes / pathology. Humans. Liver / embryology. Liver / metabolism. Lung Neoplasms / metabolism. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15920546.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Glypicans; 0 / Heparan Sulfate Proteoglycans
  •  go-up   go-down


87. Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, Han N, Ma Y, Di X, Gao M, Ma J, Zhang J, Cheng S, Gao Y: Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res; 2005 Jul 1;11(13):4646-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer.
  • PURPOSE: The extracellular matrix (ECM) molecule osteopontin is implicated in many pathologic processes, including inflammation, cell proliferation, ECM invasion, tumor progression, and metastasis.
  • The present study evaluated the clinical and biological importance of osteopontin in human lung cancer.
  • EXPERIMENTAL DESIGN AND RESULTS: Tissue microarrays derived from non-small cell lung cancer (NSCLC) patients were analyzed immunohistochemically.
  • Osteopontin protein expression was observed in 64.5% (205 of 318) of primary tumors and 75.5% (108 of 143) of lymph node metastases, but in only 27.9% (12 of 43) of normal-appearing bronchial epithelial and pulmonary tissues.
  • Osteopontin expression was associated with tumor growth, tumor staging, and lymph node invasion.
  • We further analyzed osteopontin levels in circulating plasma derived from 158 patients with NSCLC, 54 patients of benign pulmonary disease, and 25 healthy donors, and found that the median osteopontin levels for the three groups were 319.1, 161.6, and 17.9 ng/mL, respectively.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Sialoglycoproteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Cell Movement. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Male. Middle Aged. Osteopontin. Plasmids / genetics. Tissue Array Analysis. Transfection

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16000556.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 106441-73-0 / Osteopontin
  •  go-up   go-down


88. Herawi M, Epstein JI: Specialized stromal tumors of the prostate: a clinicopathologic study of 50 cases. Am J Surg Pathol; 2006 Jun;30(6):694-704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specialized stromal tumors of the prostate: a clinicopathologic study of 50 cases.
  • Specialized stromal tumors of the prostate encompass stromal sarcoma and stromal tumors of uncertain malignant potential (STUMP).
  • The histology in the 36 cases of STUMP not associated with sarcoma were as follows: 25 composed of stroma with scattered cytologically atypical cells associated with benign glands; 8 resembling glandular-stromal hyperplasia but with hypercellular stroma; 6 with extensive myxoid stroma; and 1 with phyllodes pattern.
  • In 3 of these cases, tumors were adherent to the rectum at the time of resection.
  • Five cases of STUMP showed local tumor growth: 1 case increased in size from 6 to 7.5 cm in 3 years and 4 cases recurred frequently necessitating multiple TURs of the prostate (n=2, n=3, n=3, n=3) over 1.1, 2, 7, and 8 years, respectively.
  • Fourteen patients with STUMP underwent radical prostatectomy (RP) soon after diagnosis; of these, 12 were organ confined where the tumor size ranged from 0.7 to 7.5 cm (mean 2.7 cm); 2 cases with a history of a 28 g TUR and a 275 g enucleation showed no residual tumor in the RP specimen.
  • One man was alive with metastasis to the lung 10 months after RP, 1 man was alive at 280 months with multiple metastases, and another died of disease at 115 months.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasms, Multiple Primary / metabolism. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / therapy. Prostatic Hyperplasia / pathology. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16723846.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Huber RM: [Lung cancer]. Internist (Berl); 2006 Jun;47(6):611-20; quiz 621
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung cancer].
  • Although various benign and malignant tumors can occur in the bronchi and lungs, lung cancer is by far the most common tumor and the leading cause of tumor death worldwide.
  • For therapeutic reasons lung cancer is classified currently as small cell (SCLC) or non small cell lung cancer (NSCLC).
  • In SCLC polychemotherapy is mandatory; in local tumor stages radiotherapy should be combined early on with chemotherapy, and in cases of complete remission, prophylactic cranial irradiation is indicated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Drug Therapy / trends. Lung Neoplasms / diagnosis. Lung Neoplasms / therapy. Radiotherapy / trends

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1563-74 [2167954.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3210-8 [11432888.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Pneumologie. 1998 May;52(5):243-8 [9654972.001]
  • [Cites] Eur Respir J. 1998 Jan;11(1):198-212 [9543294.001]
  • [Cites] BMJ. 1995 Oct 7;311(7010):899-909 [7580546.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):351-60 [14736927.001]
  • (PMID = 16767476.001).
  • [ISSN] 0020-9554
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 16
  •  go-up   go-down


90. Faraone D, Aguzzi MS, Toietta G, Facchiano AM, Facchiano F, Magenta A, Martelli F, Truffa S, Cesareo E, Ribatti D, Capogrossi MC, Facchiano A: Platelet-derived growth factor-receptor alpha strongly inhibits melanoma growth in vitro and in vivo. Neoplasia; 2009 Aug;11(8):732-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of platelet-derived growth factor receptors (PDGF-Rs) is reported to be reduced in metastatic melanoma compared with benign nevi or normal skin; we then hypothesized that PDGF-Ralpha may control growth of melanoma cells.
  • In a mouse model of primary melanoma growth, infection with the Ad-vector overexpressing PDGF-Ralpha reached a significant 70% inhibition of primary melanoma growth (P < .001) and a similar inhibition of tumor angiogenesis.
  • [MeSH-minor] Animals. Antigens, Differentiation / genetics. Antigens, Differentiation / metabolism. Cell Line, Tumor. Cell Proliferation. Flow Cytometry. Gene Expression Regulation, Neoplastic. Humans. In Situ Nick-End Labeling. MAP Kinase Kinase 3 / genetics. MAP Kinase Kinase 3 / metabolism. Mice. Mitogen-Activated Protein Kinase 12 / genetics. Mitogen-Activated Protein Kinase 12 / metabolism. Phosphorylation. Protein Array Analysis. Protein Phosphatase 2 / genetics. Protein Phosphatase 2 / metabolism. Proto-Oncogene Proteins c-jun / genetics. Proto-Oncogene Proteins c-jun / metabolism. Receptors, Immunologic / genetics. Receptors, Immunologic / metabolism. Transfection

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2008 May 15;22(10):1276-312 [18483217.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):369-78 [19118022.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(13):4543-52 [10848581.001]
  • [Cites] J Cell Sci. 2000 Aug;113 ( Pt 16):2855-63 [10910770.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(20):7751-63 [11003670.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 30;278(3):724-8 [11095975.001]
  • [Cites] J Invest Dermatol. 2000 Dec;115(6):1000-7 [11121133.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Feb;280(2):L354-62 [11159015.001]
  • [Cites] Cell Mol Life Sci. 2001 Jan;58(1):117-24 [11229810.001]
  • [Cites] Mol Cell. 2001 Feb;7(2):343-54 [11239463.001]
  • [Cites] Melanoma Res. 2001 Apr;11(2):183-8 [11333129.001]
  • [Cites] Am J Respir Cell Mol Biol. 2001 Jun;24(6):694-702 [11415934.001]
  • [Cites] Curr Opin Investig Drugs. 2001 Feb;2(2):287-97 [11816846.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2045-53 [11877278.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Mar 1;22(3):405-11 [11884282.001]
  • [Cites] Nat Genet. 2002 Dec;32 Suppl:496-501 [12454644.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19509-17 [12621062.001]
  • [Cites] Development. 2003 Oct;130(20):4769-84 [12952899.001]
  • [Cites] J Cutan Pathol. 2003 Oct;30(9):539-47 [14507401.001]
  • [Cites] J Biol Chem. 2003 Dec 5;278(49):49582-8 [14506245.001]
  • [Cites] Mol Cancer Ther. 2004 Feb;3(2):187-97 [14985459.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):400-5 [15009722.001]
  • [Cites] J Natl Cancer Inst. 2004 May 5;96(9):683-96 [15126605.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5270-82 [15289333.001]
  • [Cites] Circ Res. 1994 Oct;75(4):682-91 [7923614.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9500-4 [7568162.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 14;93(10):4617-22 [8643452.001]
  • [Cites] Oncogene. 1997 Feb 27;14(8):929-35 [9050992.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2622-9 [9409235.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2509-14 [9482916.001]
  • [Cites] Biochim Biophys Acta. 1998 Aug 19;1378(1):F79-113 [9739761.001]
  • [Cites] Growth Factors. 1999;16(3):201-16 [10372961.001]
  • [Cites] Physiol Rev. 1999 Oct;79(4):1283-316 [10508235.001]
  • [Cites] Int J Cancer. 2005 May 20;115(1):65-73 [15688405.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2796-809 [15838516.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1398-405 [15846297.001]
  • [Cites] J Am Soc Nephrol. 2005 Jul;16(7):1948-57 [15872077.001]
  • [Cites] J Korean Med Sci. 2005 Aug;20(4):555-61 [16100443.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1678-86 [16116595.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7234-42 [16243793.001]
  • [Cites] Cancer Biol Ther. 2005 Sep;4(9):1018-29 [16251803.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1896-902 [16322476.001]
  • [Cites] Cancer. 2006 May 1;106(9):2005-11 [16565971.001]
  • [Cites] Am J Pathol. 2006 Aug;169(2):643-54 [16877362.001]
  • [Cites] Mol Cancer. 2006;5:30 [16893473.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):829-34 [16969355.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2667-74 [17473198.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Sep 14;361(1):7-13 [17632076.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4934-42 [17652623.001]
  • [Cites] Mol Cell Biol. 2008 Jan;28(2):873-82 [17991896.001]
  • [Cites] Mol Cancer Ther. 2008 Mar;7(3):510-20 [18347138.001]
  • [Cites] J Invest Dermatol. 2008 Nov;128(11):2575-95 [18927540.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):1985-94 [19244105.001]
  • (PMID = 19649203.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Proto-Oncogene Proteins c-jun; 0 / Receptors, Immunologic; 0 / SIRPA protein, human; EC 2.7.1.- / Mitogen-Activated Protein Kinase 12; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.12.2 / MAP Kinase Kinase 3; EC 3.1.3.16 / Protein Phosphatase 2
  • [Other-IDs] NLM/ PMC2713586
  •  go-up   go-down


91. Bitterlich N, Muley T, Schneider J: Centre-independent detection of non-small cell lung cancer (NSCLC) by means of classification with receiver operating characteristic (ROC)-based data transformation. Anticancer Res; 2010 May;30(5):1661-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Centre-independent detection of non-small cell lung cancer (NSCLC) by means of classification with receiver operating characteristic (ROC)-based data transformation.
  • The diagnosis of non-small cell lung cancer (NSCLC) by using tumour markers needs to be improved and standardised in order to compare marker profiles from different centres.
  • A centre-independent tool based on receiver operating characteristics (ROC) curves instead of cut-off-based approaches for NSCLC diagnosis was established.
  • Carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were measured in 326 NSCLC patients and 160 patients with benign lung diseases (Heidelberg, HD) and compared to 158 NSCLC patients and 128 controls from an occupational medicine high-risk cohort (Giessen, GI).
  • The cohorts differed in tumour-stages, marker cut-offs and therefore in sensitivity for NSCLC detection.
  • The diagnosis of NSCLC based on ROC curves eliminate centre-specific differences.
  • Classification methods lead to an improvement in NSCLC diagnosis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Carcinoembryonic Antigen / biosynthesis. Cohort Studies. Female. Humans. Keratin-19 / biosynthesis. Male. Middle Aged. Models, Statistical. ROC Curve. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592358.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19
  •  go-up   go-down


92. Robinson LA: Solitary fibrous tumor of the pleura. Cancer Control; 2006 Oct;13(4):264-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the pleura.
  • BACKGROUND: The solitary fibrous tumor of the pleura (SFTP) is a rare primary tumor arising from mesenchymal cells in the areolar tissue subjacent to the mesothelial-lined pleura.
  • The tumor appears to be unrelated to malignant pleural mesothelioma, the most common primary tumor of the pleura.
  • METHODS: In just over half of these cases, the neoplasm presents as an asymptomatic mass, is often quite large, and is benign in 78% to 88% of patients.
  • The initial evaluation and diagnosis, tumor classification, surgical treatment, results of therapy, and long-term prognosis are reviewed, based on a selective review of the literature from MEDLINE beginning 1980.
  • RESULTS: Complete en bloc surgical resection is the preferred treatment of benign and malignant varieties of the tumor.
  • The pedunculated tumors attached to the visceral pleura can be effectively treated with a wedge resection of lung.
  • Sessile tumors arising on the lung require a larger lung resection.
  • Sessile tumors on the chest wall require wide local excision, often with chest wall resection because of their propensity for local recurrence.
  • CONCLUSIONS: Benign SFTP has a high cure rate and an 8% local recurrence rate that is usually amenable to curative re-excision.
  • The majority of patients with recurrent disease die of the tumor within 2 years.
  • [MeSH-major] Neoplasms, Fibrous Tissue / diagnosis. Neoplasms, Fibrous Tissue / therapy. Pleural Neoplasms / diagnosis. Pleural Neoplasms / therapy
  • [MeSH-minor] Diagnosis, Differential. Humans. Incidence. Neoadjuvant Therapy. Thoracic Surgical Procedures. Tomography, X-Ray Computed. United States / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075563.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


93. Kelly RJ, Barrett C, Swan N, McDermott R: Metastatic phyllodes tumor causing small-bowel obstruction. Clin Breast Cancer; 2009 Aug;9(3):193-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic phyllodes tumor causing small-bowel obstruction.
  • Cystosarcoma phyllodes is an important but relatively uncommon fibroepithelial breast neoplasm that accounts for 0.5%-1.0% of female breast carcinomas.
  • These usually metastasize to the lung, pleura, bone, and liver.
  • This report highlights a unique case of a metastatic phyllodes breast tumor leading to small bowel obstruction.
  • Phyllodes tumors are generally classified into histologic subtypes of benign, intermediate, and malignant, using agreed classification systems.
  • The tumor characteristics that can lead to the dedifferentiation of a relatively benign phenotype to an overt malignant process are discussed.
  • [MeSH-major] Breast Neoplasms / pathology. Ileal Neoplasms / secondary. Intestinal Obstruction / etiology. Phyllodes Tumor / pathology
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Mastectomy. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661046.001).
  • [ISSN] 1938-0666
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


94. Juretzka MM, Crawford CL, Lee C, Wilton A, Schuman S, Chi DS, Sonoda Y, Barakat RR, Abu-Rustum NR: Laparoscopic findings during adnexal surgery in women with a history of nongynecologic malignancy. Gynecol Oncol; 2006 May;101(2):327-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prior cancer history included breast (202, 77.1%), lymphoma/leukemia (16, 6.1%), colorectal (8, 3.0%), lung (7, 2.7%), multiple myeloma (5, 1.9%), head/neck (5, 1.9%), genitourinary (5, 1.9%), upper gastrointestinal (4, 1.5%), and other (10, 3.8%).
  • Median tumor diameter and CA-125 were significantly higher in women found to have a malignancy (4.7 vs. 3.7 cm, and 35 vs. 14 U/mL, respectively).
  • Twenty-one of 49 (42.9%) patients with malignancy were converted to laparotomy compared with 13/213 (6.1%) when benign disease was noted (P < 0.001).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360202.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M: MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res; 2008 May;18(5):549-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A microRNA expression screen was performed analyzing 157 different microRNAs in laser-microdissected tissues from benign melanocytic nevi (n = 10) and primary malignant melanomas (n = 10), using quantitative real-time PCR.
  • Members of the let-7 family of microRNAs were significantly downregulated in primary melanomas as compared with benign nevi, suggestive for a possible role of these molecules as tumor suppressors in malignant melanoma.
  • Interestingly, similar findings had been described for lung and colon cancer.
  • Taken together, these findings not only point to new regulatory mechanisms of early melanoma development, but also may open avenues for future targeted therapies of this tumor.


96. Liu J, Cai C, Wang D, Chen H, Cheng L, Shao W, Li S, Guan Y, Gu Y, He J: Video-assisted thoracoscopic surgery (VATS) for patients with solitary fibrous tumors of the pleura. J Thorac Oncol; 2010 Feb;5(2):240-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Video-assisted thoracoscopic surgery (VATS) for patients with solitary fibrous tumors of the pleura.
  • OBJECTIVES: To present our experience of video-assisted thoracoscopic surgery (VATS) for patients with solitary fibrous tumors of the pleura (SFTPs) and to discuss the treatment of choice of such neoplasms.
  • There were 18 pathologically benign SFTP cases (85.7%) and 3 malignant SFTP cases (14.3%).
  • [MeSH-major] Solitary Fibrous Tumor, Pleural / surgery. Thoracic Surgery, Video-Assisted

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009773.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Schlimper C, Sommer T, Flacke S, Wolff M, Schild H, Kreft B: [Radiologic features of inflammatory pseudotumors]. Rofo; 2005 Nov;177(11):1506-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inflammatory pseudotumor is a rare benign tumor entity.
  • Because inflammatory pseudotumors mimic malignant tumors both clinically and radiologically, the radiologist should be familiar with this entity.
  • Inflammatory pseudotumor most commonly involves the lung and the orbit, but it has been reported to occur in nearly every site in the body.
  • For making a definite diagnosis a biopsy is often essential.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Heart Diseases / diagnosis. Heart Diseases / radiography. Humans. Liver Diseases / diagnosis. Liver Diseases / radiography. Magnetic Resonance Imaging. Male. Orbital Pseudotumor / diagnosis. Orbital Pseudotumor / radiography. Plasma Cell Granuloma, Pulmonary / diagnosis. Plasma Cell Granuloma, Pulmonary / radiography. Radiography, Abdominal. Radiography, Thoracic. Splenic Diseases / diagnosis. Splenic Diseases / radiography. Tomography, X-Ray Computed

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16302131.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 54
  •  go-up   go-down


98. Mendes RA, Carvalho JF, Waal Iv: An overview on the expression of cyclooxygenase-2 in tumors of the head and neck. Oral Oncol; 2009 Oct;45(10):e124-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An overview on the expression of cyclooxygenase-2 in tumors of the head and neck.
  • Cyclooxygenase-2 (COX-2) levels are increased in various tumors, particularly those involving the esophagus, stomach, breast, pancreas, lung, colon, skin, urinary bladder, prostate and head and neck.
  • Thus, the literature shows increasing evidence that overexpression of the COX-2 plays an important role in tumor growth and spread of tumors by interfering with different biological processes such as cell proliferation, cellular adhesion, immune surveillance, apoptosis, and angiogenesis.
  • Furthermore, the expression of COX-2 might shed some light over the physiopathology and clinical behavior of tumors of the head and neck, including benign odontogenic neoplasms of the jaws with an aggressive behavior, such as keratocystic odontogenic tumors (KCOT).
  • Ultimately, the research of molecular markers associated with the biological behavior of tumors will help to understand the underlying molecular mechanisms and to predict the clinical outcome, leading to the development of new therapeutic applications, such as molecular-targeted treatment and patient tailored therapy.
  • [MeSH-major] Cyclooxygenase 2 / metabolism. Head and Neck Neoplasms / metabolism. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19457709.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Prostaglandins; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


99. Jo JH, Lee JH, Kim DC, Kim SH, Kwon HC, Kim JS, Kim HJ: A case of benign metastasizing leiomyoma with multiple metastasis to the soft tissue, skeletal muscle, lung and breast. Korean J Intern Med; 2006 Sep;21(3):199-201
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of benign metastasizing leiomyoma with multiple metastasis to the soft tissue, skeletal muscle, lung and breast.
  • Benign metastasizing leiomyoma (BML) is composed of well-differentiated smooth muscle cells and dense connective tissue.
  • BML affects middle-aged women who have had previous hysterectomies due to a histologically benign-appearing uterine leiomyoma.
  • She underwent a hysterectomy for the uterine leiomyoma, double oophorectomy for hormonal ablation and lung wedge resection to confirm the diagnosis.
  • The microscopic findings of the breast and lung tumor were similar to those of the benign uterine leiomyoma.
  • We report here on a rare case of benign metastasizing uterine leiomyoma that involved the soft tissue, skeletal muscles, lungs and breasts, and we include a review of the relevant literature.
  • [MeSH-major] Breast Neoplasms / secondary. Leiomyoma / pathology. Lung Neoplasms / secondary. Muscle Neoplasms / secondary. Soft Tissue Neoplasms / secondary. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chest Med. 2004 Jun;25(2):343-60 [15099894.001]
  • [Cites] AJR Am J Roentgenol. 1976 Sep;127(3):441-6 [183531.001]
  • [Cites] Arch Pathol Lab Med. 1999 Oct;123(10):960-2 [10506455.001]
  • [Cites] Pathol Res Pract. 1996 Jun;192(6):622-9; discussion 630-3 [8857651.001]
  • [Cites] Pathol Oncol Res. 1998;4(1):44-7 [9555121.001]
  • [Cites] Br J Obstet Gynaecol. 1986 Jun;93(6):646-8 [3730334.001]
  • (PMID = 17017672.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 094ZI81Y45 / Tamoxifen
  • [Other-IDs] NLM/ PMC3890726
  •  go-up   go-down


100. Policarpio-Nicolas ML, Covell J, Bregman S, Atkins K: Fine needle aspiration cytology of clear cell "sugar" tumor (PEComa) of the lung: report of a case. Diagn Cytopathol; 2008 Feb;36(2):89-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of clear cell "sugar" tumor (PEComa) of the lung: report of a case.
  • PEComa (clear cell "sugar" tumor) of the lung is a rare benign tumor of the lung probably arising from the perivascular epithelioid cells (PECs).
  • In this case report, the clinical, cytologic and immunohistochemical features clear cell "sugar" tumor of the lung are discussed and compared with the previously published literature.
  • The differential diagnosis and methods for distinguishing the various clear cells lesions in the lung are discussed.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Neoplasms, Connective and Soft Tissue / diagnosis. Neoplasms, Connective and Soft Tissue / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Epithelioid Cells / metabolism. Epithelioid Cells / pathology. Glycogen / metabolism. Humans. Lung / metabolism. Lung / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18181192.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9005-79-2 / Glycogen
  •  go-up   go-down






Advertisement